

DIANA S.M. BUIST

Kaiser Permanente Washington Health Research Institute, Kaiser Foundation Health Plan of Washington* · 1730 Minor Avenue, Suite 1600 · Seattle, Washington 98101 · Phone: (206) 287-2931 · Fax: (206) 287-2485 · E-mail: diana.s.buist@kp.org

EDUCATION

- | | |
|------|---|
| 1992 | University of California, Santa Barbara, California; B.A. Biological Sciences |
| 1995 | Yale School of Medicine, Department of Epidemiology and Public Health, New Haven, Connecticut; M.P.H. with honors in Epidemiology |
| 1999 | University of Washington, School of Public Health; Department of Epidemiology, Seattle, Washington; Ph.D. |

PROFESSIONAL POSITIONS

- | | |
|--------------|--|
| 1992-1993 | Behavioral Sciences Research Assistant, American Institutes for Research, Palo Alto, California |
| 1992-1993 | Behavioral Sciences Research Assistant, Veterans Administration's Homeless Veterans Domiciliary, Menlo Park, California |
| 1994 | American Schools of Public Health Epidemiology Intern, Maternal and Child Health Division, Centers for Disease Control, National Center for Health Statistics, Hyattsville, Maryland |
| 1994-1995 | Teaching Assistant, Principles of Epidemiology Course I and II, Yale School of Medicine, Department of Epidemiology and Public Health, New Haven, Connecticut |
| 1995-1996 | Research Assistant, Cardiovascular Health Study, Coordinating Center, Seattle, Washington |
| 1996-2001 | Research Associate I (09/96 – 06/99), Research Associate II (06/99 – 09/00), Research Associate III (09/00 – 10/01) Group Health* Center for Health Studies, Seattle, Washington |
| 2001-2005 | Assistant Scientific Investigator, Group Health* Center for Health Studies, Seattle, Washington |
| 2005-2010 | Associate Scientific Investigator, Group Health Research Institute* (formerly Center for Health Studies), Seattle, Washington |
| 2002-2007 | Affiliate Assistant Professor, Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington |
| 2004-present | Affiliate Member, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington |

**Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.*

- 2007-2011 Affiliate Associate Professor, Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington
- 2009-2011 Affiliate Associate Professor, Department of Health Services, School of Public Health, University of Washington, Seattle, Washington
- 2010-present Senior Scientific Investigator, Kaiser Permanente Washington Health Research Institute, Kaiser Foundation Health Plan of Washington,* Seattle, Washington
- 2011-present Affiliate Professor, Department of Health Services, School of Public Health, University of Washington, Seattle, Washington
- 2011-present Affiliate Professor, Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington
- 2014-2015 Senior Scholar in Residence, AcademyHealth, Washington DC
- 2016-present Director of Research and Strategic Partnerships, Kaiser Permanente Washington Health Research Institute,* Seattle, Washington

NATIONAL COMMITTEES

- 2013-present Overuse Measurement Advisory Panel, National Committee for Quality Assurance
- 2014 Veterans Administration, Next Generation Clinical Performance Measures: Patient-Centered, Clinically Meaningful and High-Value.
- 2015 Chair, Institute of Medicine workshop: Assessing and Improving Imaging Interpretation in Breast Cancer Screening, Washington, DC
- 2015-2017 Member, Committee on Advocacy and Public Policy, AcademyHealth
- 2015-2018 Member, Health Services Research Information Advisory Committee, AcademyHealth and the Cecil G. Sheps Center for Health Services Research at University of North Carolina, Chapel Hill, for the National Information Center on Health Services Research and Health Care Technology at the National Library of Medicine
- 2016-present Steering Committee for Defining Patient-Centered Metrics for Low-Value Care for AcademyHealth and the American Board of Internal Medicine Foundation
- 2016-present Member, Advisory Committee for the AcademyHealth-ABIM Foundation Low Value Care Research Community

OTHER EXPERIENCE

- 1991-1992 Health Educator, University of California, Santa Barbara, California
- 1993-1994 Adolescence Substance Abuse Prevention Educator, Yale School of Medicine, New Haven, Connecticut

- 1994 Epidemiologic consultant for the Chief of Neurology, West Haven Veterans Administration, New Haven, Connecticut
- 1999 National Cancer Institute: Fundamentals of Grant Writing for Cancer Control Science Workshop participant. American Society of Preventive Oncology. Houston, Texas
- 2000 Society for Epidemiologic Research Course: "Molecular Genetics in Epidemiologic Studies." Seattle, Washington.
- 2000-2002 Statistical and Analytic Consultant, University of Washington, School of Nursing, Seattle, Washington
- 2002 Scientific Writing Seminar, Group Health Center for Health Studies, Seattle, Washington
- 2004 Preparing to Lead Leadership Class, University of Washington, Seattle, Washington
- 2006-2008 Co-Chair, Breast Cancer Surveillance Consortium
- 2011-2012 Co-Chair, Breast Cancer Surveillance Consortium
- 2012 Office of Behavioral and Social Sciences Research, Training Institute for Dissemination and Implementation in Health, San Jose, CA
- 2012 University of Washington's Institute of Translational Health Sciences Small Pilot grant review
- 2012 American Society of Preventive Oncology Meeting Planning Committee
- 2012-2013 University of Washington School of Public Health, Department of Health Services PhD admissions committee
- 2014 Chair, "Health Care Resource Utilization – Trends, Influencers, Impact: What do we need to know" sponsored by AcademyHealth and American Board of Internal Medicine Foundation, Washington, DC
- 2015 Visiting Professor, University of North Carolina, Chapel Hill School of Public Health
- 2015 Susan G. Komen Foundation. Big Data and Breast Cancer Working Group.
- 2015-present Microseed Scientific Advisory Board
- 2015-present Athena WISDOM Study Data Safety and Monitoring Board
- 2016 NCI, Healthcare Delivery Research Program planning a workshop to discuss strategies for improving investigator capacity to conduct research in healthcare delivery settings.
- 2016 Learning from Successes and Failures of Low-Value Care Programs and Interventions. AcademyHealth and the ABIM Foundation Research Community on Low-Value Care
- 2016 Board Member, The Science Ambassador Scholarship funded by Cards Against Humanity

- 2017- VBID Health Task Force on Low-Value Care
- 2017 International Working Group on Risk Assessment and Strategies for Breast Cancer Screening and Prevention, sponsored by the Breast Cancer Research Foundation and the American Cancer Society
- 2018 AcademyHealth Annual Research Meeting Planning Committee
- 2018 American Society of Preventive Oncology Meeting Planning Committee

HONORS AND AWARDS

- 1994 Centers for Disease Control and Prevention, American Schools of Public Health, Epidemiology Intern
- 1995 M.P.H. with honors in Epidemiology, Yale School of Medicine, Department of Epidemiology and Public Health, New Haven, Connecticut
- 1997 Presenter, Student Workshop, Society for Epidemiologic Research, Edmonton, Alberta
- 1998-1999 Huckabay Teaching Fellowship recipient, University of Washington, Seattle, Washington
- 2009 Featured article on Radiology Select podcast (2009): Elmore JG, Jackson SL, Abraham L, Miglioretti DL, Carney PA, Geller BM, Yankaskas BC, Kerlikowske K, Onega T, Rosenberg RD, Sickles EA, **Buist DSM**. Variability in interpretive performance at screening mammography and radiologists' characteristics associated with accuracy. *Radiology*. 2009 December; 253(3): 641–651. PMID: PMC2786197.
- 2009 Featured article on *Radiology Select* podcast (2009): Miglioretti DL, Gard CC, Carney PA, Onega T, **Buist DSM**, Sickles EA, Kerlikowske K, Rosenberg RD, Yankaskas BC, Geller BM, Elmore JG. "When radiologists perform best: The learning curve in screening mammography interpretation," *Radiology*. 2009 Dec;253(3):632-40. PMID: PMC2786195
- 2011 Featured article on *Radiology Select* podcast (2011): **Buist DSM**, Anderson ML, Haneuse SJPA, Sickles EA, Smith RA, Carney PA, Taplin SH, Rosenberg RD, Geller BM, Onega T, Monsees B, Bassett LW, Yankaskas BC, Elmore JG, Kerlikowske K, Miglioretti DL. Influence of annual interpretive volume on screening mammography performance in the United States. *Radiology*. 2011 April; 259(1):72–84. PMID: PMC3064821
- 2012 Editor's Choice for 2012 in the Clinical Practice category in the *Journal of the American College of Radiology*: Onega T, Smith M, Miglioretti DL, Carney P, Geller B, Kerlikowske K, **Buist DS**, Rosenberg R, Smith R, Sickles EA, Haneuse S, Anderson ML, Yankaskas B. Radiologist agreement for mammographic recall by case difficulty and finding type. *J Am College Rad*. 2012;9(11): 788-794.
- 2012 Office of Behavioral and Social Sciences Research, Training Institute for Dissemination and Implementation in Health Selected Trainee, San Jose, CA

2014 2014 Herbert M. Stauffer Award for **Best Clinical Paper** for your outstanding manuscript published in *Academic Radiology* in the year 2013. Onega T, Anderson ML, Miglioretti DL, **Buist DSM**, Geller B, Bogart A, Smith RA, Sickles EA, Monsees B, Bassett L, Carney PA, Kerlikowske K, Yankaskas BC. Establishing a gold standard for test sets: variation in interpretive agreement of expert mammographers. *Acad Radiol.* 2013 Jun;20(6):731-9. PMC3741406.

OTHER PROFESSIONAL ACTIVITIES

Membership

1995-2010 Society for Epidemiologic Research
1999-present American Society for Preventive Oncology
2002-present American Association for Cancer Research
2012-present AcademyHealth

Professional Society Activities

1999 Co-Founder, American Society for Preventive Oncology's Junior Members Group
2000 American Society for Preventive Oncology, Organizer for Junior Members Sessions: "Cancer Prevention Career Promoters: Becoming Independent Scientists." Bethesda, Maryland
2001 American Society for Preventive Oncology, Organizer for Junior Members Sessions: "Work Cycle Regulators – preventing uncontrolled growth of duties by finding balance, learning how and when to say no, and avoiding common pitfalls" and "Get funded! A close look at the NIH Study Section"; and "www.networking: The How To Guide." New York, New York
2001 International Epidemiology Congress, Organizer for Career Development Sessions, "Behind Closed Doors: What really happens to your grant in NIH study section review?" And "Getting Published: The How To's" Toronto, Canada
2003 American Society for Preventive Oncology, Organizer for Junior Members Sessions: Scientific Writing – Key Concepts and Common Errors" and "The Peer Review Process – Revealed," Philadelphia, Pennsylvania
2004-2012 American Society for Preventive Oncology Board of Directors

Referee

1999- Reviewer, Preventive Medicine
2000- Reviewer, Cancer Causes and Control
2000- Reviewer, Cancer, Epidemiology, Biomarkers, and Prevention
2000- Reviewer, Journal of the American Geriatrics Society
2000- Reviewer, Health Education and Behavior
2000- Reviewer, American Journal of Preventive Medicine
2000- Reviewer, Medical Care
2001- Reviewer, Journal of Clinical Epidemiology
2001 Reviewer, Quarterly Medical Journal (UK)
2004 Reviewer, Experimental Biology and Medicine
2004 Reviewer, Natural Clinical Practice Oncology
2005- Reviewer, American Journal of Epidemiology
2005- Reviewer, Journal of General Internal Medicine
2006- Reviewer, Journal American Medical Association

| | |
|-----------|---|
| 2006- | Reviewer, Journal National Cancer Institute |
| 2008-2014 | Editorial Board, Cancer, Epidemiology, Biomarkers, and Prevention |
| 2013 | Reviewer, The Breast |
| 2013 | Reviewer, The American Journal of Managed Care |
| 2014- | Reviewer, eGEMS |
| 2018 | Reviewer, Aging |

PEER-REVIEW STUDY SECTIONS

1. NIH Health Services Organization and Delivery (HSOD): February 2009; June 2009; June 2010; October 2011, June 2012; February 2015; June 2019
2. Susan G. Komen Foundation. January 2009
3. NIH Special Emphasis Panel: ZRG1 IMSTJ 15, June 2011
4. NIH Special Emphasis Panel: ZRG1 HDMQ 54, May 2011
5. PCORI Scientific Reviewer for Improving Infrastructure for Conducting Patient-Centered Outcomes Research, November 2013
6. AcademyHealth New Investigator Small Grant Program, November 2014
7. Office of Behavioral and Social Sciences Research, Training Institute for Dissemination and Implementation in Health Application Review; March 2013, March 2014
8. Shanghai Ministry of Health, Grant Review, October 2011
9. Institute of Translational Health Sciences, University of Washington, Pilot Projects, December 2012
10. Patient Centered Outcomes Research Institute, Cycle 3 2015 Broads and PCS Merit Review, May 2016, April 2018
11. AcademyHealth New Investigator Small Grant Program
12. NIH Smoking Cessation within the Context of Lung Cancer Screening RFA-CA-15-011, April 2016
13. The Donaghue Foundation Great Value grant portfolio, 2016-present.
14. NIH Dissemination and Implementation Research in Health study section, February 2017.
15. Robert Wood Johnson Foundation, Health Data for Action: Leveraging Health Data for Actionable Insights, July 2017

AWARDED PEER-REVIEWED PUBLICATIONS

1. Editor's Choice in the Clinical Practice category in the 9(11) issue of Journal of the American College of Radiology: Onega T, Smith M, Miglioretti DL, Carney P, Geller B, Kerlikowske K, **Buist DS**, Rosenberg R, Smith R, Sickles EA, Haneuse S, Anderson ML, Yankaskas B. Radiologist agreement for mammographic recall by case difficulty and finding type. J Am College Rad. 2012;9(11): 788-794. PMC3653418.
2. Featured article on RADIOLOGY Select podcast Volume 4 (2013): **Buist DSM**, Anderson ML, Haneuse SJPA, Sickles EA, Smith RA, Carney PA, Taplin SH, Rosenberg RD, Geller BM, Onega T, Monsees B, Bassett LW, Yankaskas BC, Elmore JG, Kerlikowske K, Miglioretti DL. Influence of annual interpretive volume on screening mammography performance in the United States. Radiology. 2011 Apr;259(1):72-84. PMC3064821.

3. Featured article on RADIOLOGY Select podcast Volume 4 (2013): Elmore JG, Jackson SL, Abraham L, Miglioretti DL, Carney PA, Geller BM, Yankaskas BC, Kerlikowske K, Onega T, Rosenberg RD, Sickles EA, **Buist DSM**. Variability in interpretive performance at screening mammography and radiologists' characteristics associated with accuracy. *Radiology*. 2009 Dec;253(3):641-651. PMC2786197.
4. Featured article on Radiology Select podcast Volume 4 (2013): Miglioretti DL, Gard CC, Carney PA, Onega T, **Buist DSM**, Sickles EA, Kerlikowske K, Rosenberg RD, Yankaskas BC, Geller BM, Elmore JG. When radiologists perform best: The learning curve in screening mammography interpretation. *Radiology*. 2009 Dec;253(3):632-40. PMC2786195.

PEER-REVIEWED PUBLICATIONS

1. **Buist DSM**, LaCroix AZ, Newton KM, Keenan NL. Are long-term hormone replacement therapy users different from short-term and never users? *Am J Epidemiol* 1999;149(3):275-81.
2. Anderson LA, Caplan LS, **Buist DSM**, Newton KM, Curry SJ, Scholes D, LaCroix AZ. Perceived barriers and recommendations concerning hormone replacement therapy counseling among primary care providers. *Menopause*. 1999 Summer;6(2):161-6..
3. Keenan NL, Anderson LA, LaCroix AZ, Newton KM, **Buist DS**. Helping women achieve long-term continuance of menopausal estrogen replacement therapy (ERT) and hormone replacement therapy(HRT). *Menopause*. 1999 Summer;6(2):179-80.
4. LaCroix AZ, Newton KM, **Buist DSM**, Curry SJ, Scholes D, Anderson LA, Keenan NL. A population-based strategy for improving informed decision-making about hormone replacement therapy in managed care settings. *Women's Health Issues* 1999;9:306-18.
5. Chan KA, Andrade SE, Boles M, **Buist DSM**, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. *J Am Geriatr Soc*. 2000 Sep;48(9):1126-31.
6. **Buist DSM**, LaCroix AZ, Black DM, Harris F, Blank J, Ensrud K, Edgerton D, Rubin S, Fox KM. Inclusion of older women in randomized clinical trials: factors associated with taking study medication in the fracture intervention trial. *J Am Geriatr Soc* 2000; 48(9):1126-31.
7. **Buist DSM**, LaCroix AZ, Barlow WE, White E, Weiss NS. Bone mineral density and breast cancer risk in postmenopausal women. *J Clin Epidemiol*. 2001 Apr;54(4):417-22.
8. **Buist DSM**, LaCroix AZ, Barlow WE, White E, Bauer D, Cauley JA, Weiss NS. Bone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women (United States). *Cancer Causes Control*. 2001 Apr;12(3):213-22.
9. Phelan EA, **Buist DSM**, Anderson LA, Newton KM, Delaney KM, LaCroix AZ. Understanding attitudes of older women toward hormone replacement therapy. *Prev Med*. 2001 Jan;32(1):49-56.
10. Barlow WE, Taplin S, Yoshida C, **Buist DSM**, Seger D, Brown M. A cost comparison of mastectomy versus breast conserving therapy for early-stage breast cancer. *J Natl Cancer Inst*. 2001 Mar;93(6):447-55.

11. Newton KM, LaCroix AZ, **Buist DSM**, Anderson LA, Delaney KM. What factors account for differences for hormone replacement therapy prescribing frequency? *Maturitas*. 2001 Jul;39(1):1-10.
12. Donahue JG, Chan KA, Andrade SE, Beck A, Boles M, **Buist DSM**, Carey VJ, Chandler JM, Chase GA, Ettinger B, Fishman P, Goodman M, Guess HA, Gurwitz JH, LaCroix AZ, Levin TR, Platt R. Gastric and duodenal safety of daily alendronate. *Maturitas*. 2001 Jul;39(1):1-10.
13. Andrade SE, Gurwitz JH, Chan KA, Donahue JG, Beck A, Boles M, **Buist DSM**, Goodman M, LaCroix AZ, Levin TR, Platt R. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. *Maturitas*. 2001 Jul;39(1):1-10.
14. Newton KM, LaCroix AZ, **Buist DSM**, Delaney KM, Anderson LA. Women's responses to a mailed hormone replacement therapy workbook. *Menopause*. 2001 Sep-Oct;8(5):361-7.
15. Green BB, McAfee T, Hindmarsh M, Madsen L, Caplow M, **Buist DSM**. Effectiveness of telephone support in increasing physical activity levels in primary care patients. *Am J Prev Med*. 2002 Apr;22(3):177-83.
16. *Putnam KG, **Buist DS**, Fishman P, Andrade SE, Boles M, Chase GA, Goodman MJ, Gurwitz JH, Platt R, Raebel MA, Chan KA. Chronic disease score as a predictor of hospitalization. *Epidemiology*. 2002 May;13(3):340-6.
17. Newton KM, **Buist DSM**, Keenan NL, Anderson LA, LaCroix AZ. Use of alternative therapies for menopause symptoms: results of a population-based survey. *Obstet Gynecol*. 2002 Jul;100(1):18-25. Erratum in: *Obstet Gynecol*. 2003 Jan;101(1):205.
18. **Buist DSM**, LaCroix AZ, Manfredonia D, Abbott T. Identifying postmenopausal women at high fracture risk in populations: a comparison of three strategies. *J Am Geriatr Soc*. 2002 Jun;50(6):1031-8.
19. Andrade SE, Majumdar, SR, Chan KA, **Buist DSM**, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. *Arch Intern Med*. 2003 Sep;163(17):2052-7.
20. Brennehan SK, LaCroix AZ, **Buist DSM**, Chen YT, Abbott TA III. Evaluation of decision rules to identify postmenopausal women for intervention related to osteoporosis. *Dis Manag*. 2003 Fall;6(3):159-68.
21. Field TS, Cernieux J, **Buist DSM**, Geiger A, Lamerato L, Hart G, Bachman D, Krajenta R, Greene S, Hornbrook MC, Ansell G, Herrinton L, Reed G. Retention of enrollees following a cancer diagnosis within health maintenance organizations in the Cancer Research Network. *J Natl Cancer Inst* 2004;96:148-152.
22. Kerlikowske K, Miglioretti DL, Ballard-Barbash R, Weaver DL, **Buist DSM**, Barlow WE, Cutter G, Geller BM, Yankaskas B, Taplin SH, Carney PA. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screening population. *J Clin Oncol*. 2003 Dec;21(23):4314-21.
23. Taplin SH, Ichikawa L, **Buist DSM**, Seger D, White E. Evaluating organized breast cancer screening implementation: the prevention of late stage disease? *Cancer Epidemiol Biomarkers Prev*. 2004 Feb;13(2):225-34.

24. **Buist DSM**, LaCroix AZ, Brenneman SK, Abbott T 3rd. A population-based osteoporosis screening program: who does not participate and what are the consequences? *J Am Geriatr Soc*. 2004 Jul;52(7):1130-7.
25. *Casso D, **Buist DSM**, Taplin SH. Quality of life of 5-10 year breast cancer survivors diagnosed between age 40 and 49. *Health Qual Life Outcomes*. 2004 May;2:25. PMC437638.
26. *Oestreicher N, Lehman CD, Seger DJ, **Buist DSM**, White E. The incremental contribution of clinical breast examination to invasive cancer detection in a mammography screening program. *AJR Am J Roentgenol*. 2005 Feb;184(2):428-32.
27. **Buist DSM**, Anderson ML, Taplin SH, LaCroix AZ. The relationship between breast density and bone mineral density in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2004 Jul;13(7):1094-8.
28. **Buist DSM**, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40-49 years. *J Natl Cancer Inst*. 2004 Oct;96(19):1432-40.
29. **Buist DSM**, Newton KM, Miglioretti DL, Beverly K, Connelly MT, Andrade S, Hartsfield CL, Wei F, Chan KA, Kessler L. Hormone therapy prescribing patterns in the United States. *Obstet Gynecol*. 2004 Nov;104(5 Pt 1):1042-50.
30. *Aiello EJ, **Buist DSM**, White E, Seger D, Taplin SH. Rate of breast cancer diagnoses among post-menopausal women with self-reported breast symptoms. *J Am Board Fam Pract*. 2004 Nov-Dec;17(6):408-15.
31. White E, Miglioretti DL, Yankaskas BC, Geller BM, Rosenberg RD, Kerlikowske K, Saba L, Vacek PM, Carney PA, **Buist DSM**, Oestreicher N, Barlow W, Ballard-Barbash R, Taplin SH. Biennial versus annual mammography and the risk of late-stage breast cancer. *J Natl Cancer Inst*. 2004 Dec;96(24):1832-9.
32. *Aiello EJ, **Buist DSM**, White E, Porter PL. Association between mammographic breast density and breast cancer tumor characteristics. *Cancer Epidemiol Biomarkers Prev*. 2005 Mar;14(3):662-8.
33. LaCroix AZ, **Buist DSM**, Brenneman S, Abbott T. Evaluation of three population-based strategies for fracture prevention: results of the osteoporosis population-based risk assessment (OPRA) trial. *Med Care*. 2005 Mar;43(3):293-302.
34. El-Bastawissi AY, Aiello EJ, **Buist DSM**, Taplin SH. Previous pregnancy outcome and breast density (United States). *Cancer Causes Control*. 2005 May;16(4):407-17.
35. Newton KM, **Buist DSM**, Miglioretti DL, Beverly K, Hartsfield CL, Chan KA, Andrade SE, Wei F, Connelly MT, Kessler L. The impact of comorbidities on hormone use. After the 2002 release of the Women's Health Initiative. *J Gen Intern Med*. 2005 Apr;20(4):350-6. PMC1490092.
36. *Young LE, Cunningham SL, **Buist DSM**. Lone mothers are at higher risk for cardiovascular disease compared to partnered mothers. Data from the National Health and Nutrition Examination Survey III (NHANES III). *Health Care Women Int*. 2005 Aug;26(7):604-21.

37. Field TS, **Buist DSM**, Doubeni C, Enger S, Fouayzi H, Hart G, Korner EJ, Lamerato L, Bachman DJ, Ellis J, Herrinton L, Hornbrook MC, Krajenta R, Liu L, Yao J. Disparities and survival among breast cancer patients. *J Natl Cancer Inst.* 2004 Dec;96(24):1832-9.
38. Wei F, Miglioretti DL, Connelly MT, Andrade SE, Newton KM, Hartsfield CL, Chan KA, **Buist DSM**. Changes in women's use of hormones after the Women's Health Initiative estrogen and progestin trial by race, education, and income. *J Natl Cancer Inst Monogr.* 2005;(35):106-12.
39. Hartsfield CL, Connelly MT, Newton KM, Andrade SE, Wei F, **Buist DSM**. Health system responses to the Women's Health Initiative findings on estrogen and progestin: organizational response. *J Natl Cancer Inst Monogr.* 2005;(35):113-5.
40. *Boudreau DM, **Buist DSM**, Rutter CM, Fishman PA, Beverly KR, Taplin S. Impact of hormone therapy on false-positive recall rates and costs among women undergoing screening mammography. *Med Care.* 2006 Jan;44(1):62-9.
41. Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, **Buist DSM**, Geller BM, Key CR, Maygarden SJ, Ballard-Barbash R. Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. *Cancer.* 2006 Feb;106(4):732-42.
42. Hass JS, Geller B, Miglioretti DL, **Buist DSM**, Nelson DE, Kerlikowske K, Carney PA, Breslau ES, Dash S, Canales MK, Ballard-Barbash R. Changes in the newspaper coverage about hormone therapy with the release of new medical evidence. *J Gen Intern Med.* 2006 Apr;21(4):304-9. PMC1484740.
43. *Boudreau DM, Rutter CM, **Buist DS**. The influence of statin use on breast density. *Cancer Epidemiol Biomarkers Prev.* 2006 May;15(5):1026-9. PMC2066203.
44. Geller BM, Ichikawa L, **Buist DSM**, Sickles EA, Carney P, Yankaskas B, Dignan M, Kerlikowske K, Yabroff KR, Barlow W, Rosenberg R. Improving the concordance of mammography assessment and management recommendations. *Radiology.* 2006 Oct;241(1):67-75.
45. Rosenberg RD, Yankaskas BC, Abraham L, Sickles EA, Lehman C, Geller BM, Carney PA, Kerlikowske K, **Buist DSM**, Weaver D, Barlow WE, Ballard-Barbash R. Performance benchmarks for screening mammography. *Radiology.* 2006 Oct;241(1):55-66.
46. *Aiello EA, **Buist DSM**, White E. Do breast cancer risk factors modify the association between hormone therapy and mammographic breast density? (United States) *Arch Intern Med.* 2006 Dec;166(22):2469-77.
47. *Crest AB, Aiello EJ, Anderson ML, **Buist DSM**. Varying levels of family history of breast cancer in relation to mammographic breast density (United States). *Cancer Epidemiol Biomarkers Prev.* 2006 May;15(5):1026-9.
48. Barlow WE, White E, Ballard-Barbash, Vacek PM, Titus-Ernstoff ET, Carney PA, Tice JA, **Buist DSM**, Geller BM, Rosenberg R, Yankaskas BC, Kerlikowske K. Prospective breast cancer risk prediction model among women undergoing screening mammography. *J Natl Cancer Inst.* 2006 Sep;98(17):1204-14.
49. Enger SM, Thwin SS, **Buist DSM**, Field T, Frost F, Geiger AM, Lash TL, Prout M, Yood MU, Wei F, Silliman RA. Breast cancer treatment among older women in integrated health care settings. *J Clin Oncol.* 2006 Sep;24(27):4377-83. PMC1913483.

50. Tice JA, Kanaya A, Hue T, Rubin S, **Buist DSM**, LaCroix A, Lacey JV, Cauley JA, Litwack S, Brinton LA, Bauer DC. Risk factors for mortality in middle-aged women. *Arch Intern Med*. 2006 Dec;166(22):2469-77.
51. **Buist DSM**, Aiello EJ, Miglioretti DM, White E. Mammographic breast density, dense area and breast area by phase in the menstrual cycle. *Cancer Epidemiol Biomarkers Prev*. 2006 Nov;15(11):2303-6.
52. Doubeni CA, Field TA, **Buist DSM**, Korner EJ, Bigelow C, Lamerato L, Herrinton L, Quinn VP, Hart G, Hornbrook MC, Gurwitz JH, Wagner EH. Racial differences in tumor stage and survival for colorectal cancer in an insured population. *Cancer*. 2007 Feb;109(3):612-20.
53. Carney PA, Abraham LA, Miglioretti DL, Yabroff KR, Sickles EA, **Buist DSM**, Kasales CJ, Geller BM, Rosenberg RD, Dignan MB, Weaver DL, Kerlikowske K; Breast Cancer Surveillance Consortium. Factors associated with imaging and procedural events used to detect breast cancer following screening mammography. *AJR Am J Roentgenol*. 2007 Feb;188(2):385-92.
54. Geiger AM, Thwin SS, Lash TL, **Buist DSM**, Prout MN, Wei F, Field TS, Yood MU, Frost FJ, Enger SM, Silliman RA. Recurrences and second primary breast cancers in older women with initial early-stage disease. *Cancer*. 2007 Mar;109(5):966-74.
55. Haas JS, Miglioretti DL, Geller B, **Buist DSM**, Nelson DE, Kerlikowske K, Carney PA, Dash S, Breslau ES, Ballard-Barbash R. Average household exposure to newspaper coverage about the harmful effects of hormone therapy and population-based declines in hormone therapy use. *J Gen Intern Med*. 2007 Jan;22(1):68-73. PMC1824785.
56. Lash TL, Fox MP, Thwin SS, Geiger AM, **Buist DSM**, Wei F, Field TS, Yood MU, Frost FJ, Quinn VP, Prout MN, Silliman RA. Using probabilistic corrections to account for abstractor agreement in medical record reviews. *Am J Epidemiol*. 2007 Jun;165(12):1454-61. Epub 2007 Apr 3.
57. Kerlikowske K, Ichikawa L, Miglioretti DL, **Buist DSM**, Vacek PM, Smith-Bindman R, Yankaskas B, Carney PA, Ballard-Barbash R; National Institutes of Health Breast Cancer Surveillance Consortium. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. *J Natl Cancer Inst*. 2007 Mar;99(5):386-95.
58. Boudreau DM, Yu O, Miglioretti DL, **Buist DSM**, Heckbert S, Daling J. Statin use and breast cancer risk in a large population-based setting. *Cancer Epidemiol Biomarkers Prev*. 2007 Mar;16(3):416-21. PMC2065858.
59. Lash TL, Fox MP, **Buist DSM**, Wei F, Field TS, Frost FJ, Geiger AM, Quinn VP, Yood MU, Silliman RA. Mammography surveillance and mortality in older breast cancer survivors. *J Clin Oncol*. 2007 Jul 20;25(21):3001-6. Epub 2007 Jun 4.
60. *Aiello EJ, **Buist DSM**, Wagner EH, Tuzzio L, Greene SM, Lamerato LE, Field TS, Herrinton LJ, Haque R, Hart G, Bischoff KJ, Geiger AM. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. *Breast Cancer Res Treat*. 2008 Feb;107(3):397-403. Epub 2007 Mar 28.
61. *Owusu C, **Buist DSM**, Field TS, Lash TL, Thwin SS, Geiger AM, Quinn VP, Frost F, Prout A, Yood MU, Wei F, Silliman RA. Predictors of tamoxifen discontinuation among

older women with estrogen-receptor positive breast cancer. *J Clin Oncol*. 2008 Feb;26(4):549-55. Epub 2007 Dec 10.

62. **Buist DSM**, Ichikawa L, Prout MN, Yood MU, Field TS, Owusu C, Geiger AM, Quinn VP, Wei F, Silliman RA. Receipt of appropriate primary breast cancer therapy and adjuvant therapy are not associated with obesity in older women with access to health care. *J Clin Oncol*. 2007 Aug;25(23):3428-36.
63. Twinn SS, Clough-Gorr KM, McCarty MC, Lash TL, Alford SH, **Buist DSM**, Enger SM, Field TS, Frost F, Wei F, Silliman RA. Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study. *BMC Med Res Methodol*. 2007 Jun;7:23. PMC1919388.
64. Kerlikowske K, Miglioretti DL, **Buist DSM**, Walker R, Carney PA; National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. *J Natl Cancer Inst*. 2007 Sep;99(17):1335-9. Epub 2007 Aug 14.
65. Miglioretti DL, Smith-Bindman R, Abraham L, Brenner RJ, Carney PA, Aiello Bowles EJ, **Buist DSM**, Elmore JG. Radiologist characteristics associated with interpretive performance of diagnostic mammography. *J Natl Cancer Inst*. 2007 Dec;99(24):1854-63. Epub 2007 Dec 11.
66. *Chubak J, **Buist DSM**, Boudreau DM, Rossing M, Lumley T, Weiss NS. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. *Breast Cancer Res Treat*. 2008 Nov;112(1):123-32. Epub 2007 Dec 6.
67. Field TS, Doubeni C, Fox MP, **Buist DSM**, Wei F, Geiger AM, Quinn VP, Lash TL, Prout MN, Yood MU, Frost FJ, Silliman RA. Under utilization of surveillance mammography among older breast cancer survivors. *J Gen Intern Med*. 2008 Feb;23(2):158-63. PMC2359172.
68. Yood MU, Owusu C, **Buist DSM**, Geiger AM, Field TS, Thwin SS, Lash TL, Prout MN, Frost FJ, Wei F, Quinn VP, Silliman RA. Mortality impact of less-than-standard therapy in older breast cancer patients. *J Am College Surg*. 2008 Jan;206(1):66-75. Epub 2007 Oct 3.
69. Newton KM, **Buist DSM**, Yu O, Hartsfield CL, Andrade SE, Wei F, Connelly MT, Chan KA. Hormone therapy initiation after the Women's Health Initiative. *Menopause*. 2008 May-Jun;15(3):487-93.
70. Lehman CD, Rutter CM, Eby PR, White E, **Buist DSM**, Taplin SH. Lesion and patient characteristics associated with malignancy after a probably benign finding on community practice mammography. *AJR Am J Roentgenol*. 2008 Feb;190(2):511-5.
71. Geiger AM, **Buist DSM**, Greene SM, Altschuler A, Field TS. Survivorship research based in integrated healthcare delivery systems: the Cancer Research Network. *Cancer*. 2008 Jun;112(11 Suppl):2617-26.
72. Goldman LE, Haneuse SJ, Miglioretti DL, Kerlikowske K, **Buist DS**, Yankaskas B, Smith-Bindman R; National Cancer Institute Sponsored Breast Cancer Surveillance Consortium. An assessment of the quality of mammography care at facilities treating medically vulnerable populations. *Med Care*. 2008 Jul;46(7):701-8. PMC2674332.

73. Boudreau DM, Yu O, **Buist DSM**, Miglioretti DL. Statin use and prostate cancer risk in a large population based setting. *Cancer Causes Control*. 2008 Sep;19(7):767-74. PMC2575006.
74. *Park A, **Buist DSM**, Tiro JA Taplin SH. Mediating factors in the relationship between income and mammography use in low-income insured women. *J Womens Health (Larchmt)*. 2008 Oct;17(8):1371-8. PMC2944414.
75. Terry MB, **Buist DSM**, Trentham-Dietz A, James-Todd TM, Liao Y. Nonsteroidal anti-inflammatory drugs and change in mammographic density: a cohort study using pharmacy records on over 29,000 postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2008 May;17(5):1088-95.
76. *Welsh M, **Buist DSM**, Aiello Bowles E, Anderson ML, Elmore J, Li C. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. *Breast Cancer Res Treat*. 2009 Apr;114(3):549-58. Epub 2008 Apr 25. PMC2692346.
77. Sprague BL, Trentham-Dietz A, Terry MB, Nichols HB, Bersch AJ, **Buist DSM**. Fertility drug use and mammographic breast density in a mammography screening cohort of premenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2008 May;17(5):1088-95. PMC2621442.
78. Kerlikowske K, Walker R, Miglioretti DL, Desai A, Ballard-Barbash R, **Buist DSM**. Obesity, mammography use and accuracy, and advanced breast cancer risk. *J Natl Cancer Inst*. 2008 Dec;100(23):1724-33. PMC 2734114.
79. Yu O, Boudreau D, **Buist DSM**, Miglioretti D. Statin use and female reproductive organ cancer risk in a large population based setting. *Cancer Causes Control*. 2009 Jul;20(5):609-16. PMC3041638.
80. *Phipps AI, **Buist DSM**. Validation of self-reported history of hysterectomy and oophorectomy. *Menopause*. 2009 May-Jun;16(3):576-81. PMC2695678.
81. Fenton JJ, Reid RJ, Baldwin L-M, Elmore JG, **Buist DSM**, Franks P. Influence of primary care use on population delivery of colorectal cancer screening. *Cancer Epidemiol Biomarkers Prev*. 2009 Feb;18(2):640-5. PMC2731702.
82. *Chubak J, Bowles EA, Terry MB, Trentham-Dietz A, **Buist DSM**. Antidepressant medications and change in mammographic density in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2009 Feb;18(2):676-9. PMC2640441.
83. Carney PA, Kettler M, Cook AJ, Geller BM, Karliner L, Miglioretti DL, Bowles EA, **Buist DS**, Gallagher TH, Elmore JG. An assessment of the likelihood, frequency, and content of verbal communication between radiologists and women receiving screening and diagnostic mammography. *Acad Radiol*. 2009 Sep;16(9):1056-63. PMC2746626.
84. **Buist DSM**, Anderson ML, Reed SD, Aiello Bowles EJ, Fitzgibbons ED, Gandara JC, Seger D, Newton KM. Short-term hormone therapy suspension and mammography recall: a randomized trial. *Ann Intern Med*. 2009 Jun;150(11):752-65. PMC2803099.
85. Reed SD, **Buist DSM**, Anderson ML, Bowles EAJ, Fitzgibbons D, Seger D, Newton KM. Short-term (1-2 mo) hormone therapy cessation before mammography. *Menopause*. 2009 Nov-Dec;16(6):1125-31. PMC2783807.
86. McTiernan A, Wang CY, Sorensen B, Xiao L, **Buist DSM**, Bowles EJA, White E, Rossing MA, Potter J, Urban N. No effect of aspirin on mammographic density in a randomized

controlled clinical trial. *Cancer Epidemiol Biomarkers Prev.* 2009;18:1524-30. PMC2689709.

87. **Buist DSM**, Chubak J, Prout M, Yood MU, Bosco JL, Thwin SS, Gold HT, Owusu C, Field TS, Quinn VP, Wei F, Silliman RA. Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence. *J Clin Oncol.* 2009 Sep;27(27):4508-14. PMC2754903.
88. Elmore JG, Jackson SL, Abraham L, Miglioretti DL, Carney PA, Geller BM, Yankaskas BC, Kerlikowske K, Onega T, Rosenberg RD, Sickles EA, **Buist DSM**. Variability in interpretive performance at screening mammography and radiologists' characteristics associated with accuracy. *Radiology.* 2009 Dec; 253(3): 641–651. PMC2786197.
89. Miglioretti DL, Gard CC, Carney PA, Onega TL, **Buist DSM**, Sickles EA, Kerlikowske K, Rosenberg RD, Yankaskas BC, Geller BM, Elmore JG. When radiologists perform best: the learning curve in screening mammography interpretation. *Radiology.* 2009 Dec; 253(3): 632–640. PMC2786195.
90. Bosco JLF, Lash TL, Prout MN, **Buist DSM**, Geiger AM, Haque R, Wei F, Silliman RA; BOW Investigators. Breast cancer recurrence in older women five to ten years after diagnosis. *Cancer Epidemiol Biomarkers Prev.* 2009;18(11):2979-2983. PMC2784208.
91. Gold HT, Thwin SS, **Buist DSM**, Field TS, Wei F, Yood MU, Quinn V, Lash TL, Quinn VP, Geiger AM, Silliman RA. Delayed radiotherapy for breast cancer patients in integrated delivery systems. *Am J Manag Care.* 2009;15:785-89. PMC2916649.
92. Bosco JLF, Silliman RA, Thwin SS, Geiger AM, **Buist DSM**, Prout MN, Yood MU, Haque R, Wei F, Lash TL. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. *J Clin Epidemiol.* 2010 Jan; 63(1): 64–74. PMC2789188.
93. Taplin SH, Abraham L, Geller BM, Yankaskas BC, **Buist DS**, Smith-Bindman R, Lehman C, Weaver D, Carney PA, Barlow WE. Effect of previous benign breast biopsy on the interpretive performance of subsequent screening mammography. *J Natl Cancer Inst.* 2010 Jul;102(14):1040-51. PMC2907407.
94. Fenton JJ, Elmore JG, **Buist DSM**, Reid RJ, Tancredi DJ, Baldwin LM. Longitudinal adherence with fecal occult blood test screening in community practice. *Ann Fam Med.* 2010;8(5):397-401. PMC2939414.
95. Aiello Bowles EJ, Anderson ML, Reed SD, Newton KM, Fitzgibbons ED, Seger D, **Buist DSM**. Mammographic breast density and tolerance for short-term postmenopausal hormone therapy suspension. *J Womens Health (Larchmt).* 2010 Aug; 19(8):1467–1474. PMC2941404.
96. Yankaskas BC, Haneuse S, Kapp JM, Kerlikowske K, Geller B, **Buist DSM**, for the Breast Cancer Surveillance Consortium. Performance of first mammography examination in women younger than 40 years. *J Natl Cancer Inst.* 2010 May;102(10):692-701. PMC2902813.
97. Kapp JM, Walker R, Haneuse S, **Buist DSM**, Yankaskas BC. Are there racial/ethnic disparities among women younger than 40 undergoing mammography? *Breast Cancer Res Treat.* 2010 Nov;124(1):213-22. PMC2927744.
98. Elmore JG, Aiello Bowles EJ, Geller B, Vukshich Oster N, Carney PA, Miglioretti DL, **Buist DM**, Kerlikowske K, Sickles EA, Onega T, Rosenberg RD, Yankaskas BC. Radiologists'

- attitudes and use of mammography audit reports. *Acad Radiol.* 2010 Jun;17(6):752-60. PMC2894027.
99. Cox B, Ballard-Barbash R, Broeders M, Dowling E, Malilia N, Shumak R, Taplin S, **Buist D**, Miglioretti D. Recording of hormone therapy and breast density in breast screening programs: summary and recommendations of the International Cancer Screening Network. *Breast Cancer Res Treat.* 2010 Dec;124(3):793-800. Epub 2010 Apr 23.
 100. Kerlikowske K, Cook AJ, **Buist DSM**, Cummings SR, Vachon C, Vacek P, Miglioretti DL for the National Cancer Institute Sponsored Breast Cancer Surveillance Consortium. Breast cancer risk by breast density, age, menopause, and postmenopausal hormone therapy use. *J Clin Oncol.* 2010 Aug;28(24):3830-7. PMC2940400.
 101. *Phipps AI, Ichikawa L, Bowles EJ, Carney PA, Kerlikowske K, Miglioretti DL, **Buist DS**. Defining menopausal status in epidemiologic studies: A comparison of multiple approaches and their effects on breast cancer rates. *Maturitas.* 2010 Sep;67(1):60-6. PMC2922404.
 102. *Phipps AI, Li CL, Kerlikowske K, Barlow WE, **Buist DSM**. Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. *Cancer Epidemiol Biomarkers Prev.* 2010 Jun;19(6):1643-54. PMC2882996.
 103. **Buist DSM**, Abraham L, Barlow WE, Krishnaraj A, Holdridge RC, Sickles EA, Carney PA, Kerlikowske K, Geller BM for the Breast Cancer Surveillance Consortium. Diagnosis of second breast cancer events after an initial early-stage breast cancer diagnosis. *Breast Cancer Res Treat.* 2010 Dec;124(3):863-73. PMC2976764.
 104. Newton KM, Anderson ML, Reed SD, Bowles EJA, **Buist DSM**. Factors associated with non-compliance with hormone therapy cessation before screening mammography. *Climacteric.* 2011 Apr;14(2):268-74. Epub 2010 Oct 27.
 105. *Phipps AI, **Buist DS**, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. *Breast Cancer Res Treat.* 2011 Apr;126(3):671-8. PMC3059326.
 106. Farhat GN, Walker R, **Buist DSM**, Onega T, Kerlikowske K. Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy Use. *J Clin Oncol.* 2010 Dec;28(35):5140-6. PMC3020688.
 107. Demartini WB, Ichikawa L, Yankaskas BC, **Buist DSM**, Kerlikowske K, Geller B, Onega T, Rosenberg RD, Lehman CD. Breast MRI in community practice: equipment and imaging techniques at facilities in the breast cancer surveillance consortium. *J Am Coll Radiol.* 2010 Nov;7(11):878-84. PMC2994070.
 108. Miglioretti DL, Walker R, Weaver DL, **Buist DSM**, Taplin SH, Carney PA, Rosenberg RD, Dignan MB, Zhang ZT, White E. Accuracy of screening mammography varies by week of menstrual cycle. *Radiology.* 2011 Feb;258(2):372-9. PMC3029886.
 109. Wernli KJ, Aiello Bowles EJ, Haneuse S, Elmore JG, **Buist DSM**. Timing of follow-up after abnormal screening and diagnostic mammograms. *Am J Managed Care.* 2011 Feb;17(2):162-7. PMC3151253.
 110. **Buist DSM**, Anderson ML, Haneuse SJPA, Sickles EA, Smith RA, Carney PA, Taplin SH, Rosenberg RD, Geller BM, Onega T, Monsees B, Bassett LW, Yankaskas BC, Elmore JG, Kerlikowske K, Miglioretti DL. Influence of annual interpretive volume on screening

- mammography performance in the United States. *Radiology*. 2011 Apr; 259(1):72–84. PMC3064821.
111. Loo LWM, Wang Y, Flynn EM, Lund MJ, Bowles EJA, **Buist DSM**, Liff JM, Flagg EW, Coates RJ, Eley JW, Hsu L, Porter PL. Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. *Breast Cancer Res Treat*. 2011 May;127(1):297-308. PMC3224104.
 112. Sprague BL, Trentham-Dietz A, Gangnon RE, **Buist DSM**, Burnside ES, Bowles EJ, Stanczyk FZ, Sisney GS. Circulating sex hormones and mammographic breast density among postmenopausal women. *Horm Cancer*. 2011 Feb;2(1):62-72. PMC3035325.
 113. *Phipps AI, **Buist DSM**, Malone KE, Barlow WE, Porter PL, Kerlikowske K, Li CI.; Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. *Cancer Causes Control*. 2011 Mar;22(3):399-405. PMC3042513.
 114. Houssami N, Abraham LA, Miglioretti DL, Sickles EA, Kerlikowske K, **Buist DSM**, Geller BM, Muss HB, Irwig L. Accuracy and outcomes of screening mammography in women with a personal history of breast cancer. *JAMA*. 2011 Feb;305(8):790-9. PMC3799940.
 115. Onega T, Cook A, Kirlin B, Shi X, Alford-Teaster J, Tuzzio L, **Buist DSM**. The influence of travel time on breast cancer characteristics, receipt of primary therapy, and surveillance mammography. *Breast Cancer Res Treat*. 2011 Aug;129(1):269-75. PMC3786215.
 116. Sprague BL, Trentham-Dietz A, Gangnon RE, **Buist DSM**, Burnside ES, Bowles EA, Stanczyk FZ, Sisney GS, Skinner HG. The vitamin D pathway and mammographic breast density among postmenopausal women. *Breast Cancer Res Treat*. 2012;131(1):255-65. PMC3250989.
 117. *Tom SE, Anderson ML, Landis CA, Aiello Bowles EJ, Woods NF, Reed SD, Newton KM, **Buist DS**. Sleep problems after short-term hormone therapy suspension: secondary analysis of a randomized trial. *Menopause*. 2011;18(11):1184-90. PMC3203993.
 118. *Lowry SJ, Bowles EA, Anderson ML, **Buist DSM**. Predictors of breast density change after hormone therapy cessation: results from a randomized trial. *Cancer Epidemiol Biomarkers Prev*. 2011;20(10):2309-12. PMC3189299.
 119. Rosenberg RD, Haneuse SJPA, Geller BM, **Buist DSM**, Miglioretti DL, Brenner RJ, Smith-Bindman R, Taplin SH. Timeliness of follow-up after abnormal screening mammogram: variability of facilities. *Radiology*. 2011 Nov;261(2):404-13. PMC3198220.
 120. Carney PA, Bogart A, Geller BM, Haneuse S, Kerlikowske K, **Buist DSM**, Rosenberg R, Yankaskas BC, Onega T, Miglioretti D. Association between time spent interpreting, level of confidence, and accuracy of screening mammography. *AJR Am J Roentgenol*. 2012 Apr;198(4):970-8. PMC3654687.
 121. Zeliadt SB, **Buist DS**, Reid RJ, Grossman DC, Ma J, Etzioni R. Biopsy follow-up of prostate-specific antigen tests. *Am J Prev Med*. 2012 Jan;42(1):37-43. PMC3556898.
 122. Haneuse S, **Buist DSM**, Miglioretti DL, Anderson ML, Carney PA, Onega T, Geller BM, Kerlikowske K, Rosenberg RD, Yankaskas BC, Elmore JG, Taplin S, Smith R, Sickles EA. Mammographic interpretive volume and diagnostic mammography interpretation performance in community practice. *Radiology*. 2012 Jan;262(1):69-79. PMC3244665.
 123. Aiello Bowles EJ, **Buist DSM**, Chubak J, Yu O, Johnson J, Chestnut J, Boudreau DM. Endocrine therapy initiation from 2001 through 2008 varies by age of breast cancer diagnosis and tumor size. *J Oncol Pract*. 2012 Mar;8(2):113-20. PMC345781.

124. Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, **Buist DSM**. Adverse events after screening and follow-up colonoscopy. *Cancer Causes Control*. 2012 Feb;23(2):289-96. PMC3406732.
125. **Buist DSM**, Walker R, Aiello Bowles EJ, Carney PA, Taplin SH, Onega T, Kerlikowske K, Clinton W, Miglioretti DL. Screening mammography use among current, former, and never hormone therapy users does not explain recent declines in breast cancer incidence. *Cancer Epidemiol Biomarkers Prev*. 2012 May;21(5):720-7. PMC3348383.
126. *Phipps AI, **Buist DSM**, Malone KE, Barlow WE, Porter PL, Kerlikowske K, O'Meara ES, Li CI. Breast density, body mass index, and risk of tumor-marker defined subtypes of breast cancer. *Ann Epidemiol*. 2012 May;22(5):340-8. Epub 2012 Feb 25. PMC3338877.
127. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, O'Meara ES, **Buist DS**, Kerlikowske K, van Ravesteyn NT, Trentham-Dietz A, Mandelblatt J, Miglioretti D On behalf of the Breast Cancer Surveillance Consortium/Cancer Intervention and Surveillance Modeling Network/Evidence-based Practice Center Collaboration Group. Risk Factors for Breast Cancer for Women Aged 40 to 49 years: a systematic review and meta-analysis. *Ann Intern Med*. 2012 May;156(9):635-48. PMC3561467.
128. Van Ravesteyn NT, Miglioretti DL, Stout NK, Lee SJ, Schechter CB, **Buist DSM**, Huan H, Heijnsdijk EAM, Trentham-Dietz A, Alagoz O, Near AM, Kerlikowske K, Nelson HD, Mandelblatt JS, deKoning HJ. Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. *Ann Intern Med*. 2012 May;156(9):609-17. PMC3520058.
129. Klein G, Gold LS, Sullivan SD, **Buist DSM**, Ramsey S, Kreizenbeck K, Snell K, Trice Loggers E, Gifford J, Watkins JB, Kessler L. Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach. *J Comp Eff Res*. 2012;1(3):241-55. PMC3480224.
130. Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, Ulcickas Yood M, Barlow WE, **Buist DSM**. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. *J Natl Cancer Inst*. 2012 Jun;104(12):931-40. PMC3732250.
131. *Romaine M, Aiello Bowles EJ, Anderson ML, **Buist DSM**. Comparative effectiveness of mailed reminder letters on mammography screening compliance. *Prev Med*. 2012 Aug;55(2):127-30. PMC3694128.
132. *Pocobelli G, Chubak J, Hanson N, Drescher C, Resta R, Urban N, **Buist DSM**. Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling. *Gynecol Oncol*. 2012 Aug;126(2):229-35. PMC3383401.
133. Onega T, Smith M, Miglioretti DL, Carney P, Geller B, Kerlikowske K, **Buist DS**, Rosenberg R, Smith R, Sickles EA, Haneuse S, Anderson ML, Yankaskas B. Radiologist agreement for mammographic recall by case difficulty and finding type. *J Am College Rad*. 2012;9(11): 788-794. PMC3653418.
134. *Lowry SJ, Sprague BL, Aiello Bowles EJ, Hedman CJ, Hemming J, Hampton JM, Burnside ES, Sisney GA, **Buist DSM**, Trentham-Dietz A. Mammographic breast density and serum phytoestrogen levels. *Nutr Cancer*. 2012 Aug;64(6):783-9. PMC4055295.
135. Carlos RC, **Buist DSM**, Wernli KJ, Swan JS. Patient-centered outcomes in imaging: quantifying value. *J Am Coll Radiol*. 2012 Oct;9(10):725-8. PMC3810945.

136. Henderson LM, Hubbard RA, Onega TL, Zhu W, **Buist DSM**, Fishman P, Tosteson AN. Assessing health care use and cost consequences of a new screening modality: the case of digital mammography. *Med Care*. 2012 Dec;50(12):1045-52. PMC3650634.
137. *Dallal CM, Brinton LA, Bauer DC, **Buist DSM**, Cauley JA, Hue TF, LaCroix A, Tice JA, Chia VM, Falk R, Pfeiffer R, Pollak M, Veenstra TD, Xu X, Lacey JV, for the B-FIT Research Group. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B-FIT cohort. *Endocr Relat Cancer*. 2013 Feb;20(1):151-60. PMC4038326.
138. Clough-Gorr K, Thwin S, Bosco J, Silliman R, St. **Buist DSM**, Pawloski P, Quinn V, Prout M. Incident malignancies among older long-term breast cancer survivors and an age-matched and site-matched non-breast cancer comparison group over 10 years of follow-up. *Cancer*. 2013 Apr;119(8):1478-85. PMC3739702.
139. Aiello Bowles EJ, Boudreau DM, Chubak J, Yu O, Fujii M, Chestnut J, **Buist DS**. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. *J Oncol Pract*. 2012 Nov;8(6):e149-57. PMC3500489.
140. Hubbard RA, Zhu W, Onega TL, Fishman P, Henderson LM, Tosteson A, **Buist DS**. Effects of digital mammography uptake on downstream breast-related care among older women. *Med Care*. 2012. Dec;50(12):1053-1059. PMC3494765.
141. Kamineni A, Anderson ML, White E, Taplin SH, Porter P, Ballard-Barbash R, Malone K, **Buist DS**. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. *Cancer Causes Control*. 2013 Feb;24(2):305-12. PMC3557530.
142. Doubeni CA, Weinmann S, Adams K, Kamineni A, **Buist DSM**, Ash A, Rutter CM, Doria-Rose VP, Corley DA, Greenlee RT, Chubak J, Williams A, Kroll-Desrosiers AR, Johnson E, Webster J, Richert-Boe K, Levin TR, Fletcher RH, Weiss NS. Screening colonoscopy and risk of incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. *Ann Intern Med*. 2013 Mar;158(5 Pt 1):312-20. 312-20. PMC3752391.
143. Harvey JA, Gard CC, Miglioretti DL, Yankaskas BC, Kerlikowske K, **Buist DSM**, Geller BA, Onega TL for the Breast Cancer Surveillance Consortium. Reported mammographic density: film-screen versus digital acquisition. *Radiology*. 2013 Mar; 266(3):752-8. PMC3579169.
144. Chubak J, Rutter CM, Kamineni A, Johnson EA, Stout NK, Weiss NS, Doria-Rose VP, Doubeni CA, **Buist DSM**. Measurement in comparative effectiveness research. *Am J Prev Med*. 2013 May; 44(5):513-9. PMC3631525.
145. *Gold LS, **Buist DSM**, Loggers ET, Etzioni R, Kessler L, Ramsey SD, Sullivan SD. Advanced diagnostic breast cancer imaging: variation and patterns of care in Washington State. *J Oncol Pract*. 2013 Sep 1;9(5):e194-202. PMC3770510.
146. Hubbard R, **Buist DSM**, Zhu W, Horblyuk R, Onega T, Sprague BL, Henderson L, Lee DW, Sweet AI, Karliner L. Diagnostic imaging and biopsy pathways following abnormal screen-film and digital screening mammography. *Breast Cancer Res Treat*. 2013;138(3):879-87. PMC3640408.
147. Houssami N, Abraham LA, Kerlikowske K, **Buist DSM**, Irwig L, Lee J, Miglioretti DL. Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening. *Cancer Epidemiol Biomarkers Prev*. 2013 May; 22(5):946-961. PMC3650092.

148. Sprague BL, Trentham-Dietz A, Hedman CJ, Wang J, Hemming JDC, Hampton JM, **Buist DSM**, Bowles EJ, Sisney GS, Burnside ES. Circulating serum xenoestrogens and mammographic breast density. *Breast Cancer Res.* 2013 May;15(3):R45. PMC4053153.
149. **Buist DSM**, Knight Ross N, Reid RJ, Grossman DC. Electronic health risk assessment adoption in an integrated healthcare system. *Am J Manag Care.* 2013 Dec;19(12):11-8.
150. Schairer C, Li Y, Frawley P, Graubard BI, Wellman RD, **Buist DSM**, Kerlikowske K, Onega TL, Anderson WF, Miglioretti DL. Risk factors for inflammatory breast cancer and other invasive breast cancers. *J Natl Cancer Inst.* 2013;105:1373-1384. doi: 10.1093/jnci/djt206. PMC3776263.
151. Onega T, Anderson ML, Miglioretti DL, **Buist DSM**, Geller B, Bogart A, Smith RA, Sickles EA, Monsees B, Bassett L, Carney PA, Kerlikowske K, Yankaskas BC. Establishing a gold standard for test sets: variation in interpretive agreement of expert mammographers. *Acad Radiol.* 2013 Jun;20(6):731-9. PMC3741406.
152. *Wirtz HS, **Buist DSM**, Gralow JR, Barlow WE, Gray SL, Chubak J, Yu O, Bowles EJA, Fujii M, Boudreau DM. Frequent antibiotic use and second breast cancer events. *Cancer Epidemiol Biomarkers Prev.* 2013 Sep;22(9):1588-99. PMC3769442.
153. Carrell D, Halgrim S, Tran DT, **Buist DSM**, Chubak J, Chapman WW, Savova G. Using natural language processing to improve efficiency of manual chart abstraction in research: the case of breast cancer recurrence. *Am J Epidemiol.* 2014 Mar;179(6):749-758. PMC3939853.
154. Carney PA, Geller BM, Bogart A, Sickles EA, Smith RA, **Buist DSM**, Kerlikowske K, Onega TL, Miglioretti DL, Rosenberg R, Yankaskas BC. Feasibility and acceptability of conducting a randomized clinical trial designed to improve interpretation of screening mammography. *Acad Radiol.* 2013 Nov;20(11):1389-98. PMC4152937.
155. **Buist DSM**, Bosco JLF, Silliman RA, Taffet Gold H, Field T, Ulcickas Yood M, Quinn VP, Prout M, Lash TL. Long-term surveillance mammography and mortality in older women with a history of early stage invasive breast cancer. *Breast Cancer Res Treat.* 2013;142(1):153-63. PMC3857395.
156. Owens CL, Peterson D, Kaminen A, **Buist DS**, Weinmann S, Ross TR, Williams AE, Stark A, Adams KF, Field TS. Effects of transitioning from conventional methods to liquid-based methods on unsatisfactory Papanicolaou tests: results from a multicenter US study. *Cancer Cytopathol.* 2013 Oct;121(10):568-75. PMC3800270.
157. Wernli KJ, O'Meara ES, Kerlikowske K, Miglioretti DL, Muller CY, Onega T, Sprague BI, Henderson L, **Buist DSM**. Investigation of mammographic breast density as a risk factor for ovarian cancer. *J Natl Cancer Inst.* 2014 Jan;106(1):djt341. PMC3906993.
158. Dallal CM, Tice JA, **Buist DSM**, Bauer DC, Lacey JV, Cauley JA, Hue TF, LaCroix A, Falk RT, Pfeiffer R, Fuhrman BJ, Veenstra TD, Xu X, Brinton LA. Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT. *Carcinogenesis.* 2014 Feb;35(2):346-355. PMC3908751.
159. Henrikson N, Tuzzio L, Loggers ET, Miyoshi J, **Buist DSM**. Patient and oncologist discussions about cancer care costs. *Support Care Cancer.* 2014 Apr;22(4):961-7. Epub 2013 Nov 26. PMC3943697.
160. Geller BM, Bogart A, Carney PA, Sickles EA, Smith RA, Monsees B, Bassett LW, **Buist DM**, Kerlikowske K, Onega T, Yankaskas B, Haneuse S, Hill DA, Wallis M, Miglioretti DL. Educational interventions to improve screening mammography interpretation: a randomized, controlled trial. *AJR Am J Roentgenol.* 2014 Jun;202(6):W586-96.

PMC4276372.

161. Stout NK, Nekhlyudov L, Li L, Malin ES, Ross-Deganan D, **Buist DSM**, Rosenber MA, Alfischer M, Fletcher SW. Rapid increase in breast magnetic resonance imaging use: trends from 2000 to 2011. *JAMA Intern Med.* 2014 Jan;174(1):114-21. PMC4145846.
162. Stout NK, Lee SJ, Schechter CB, Kerlikowske K, Alagoz O, Berry D, **Buist DSM**, Cevik M, Chisholm G, de Koning HJ, Huang H, Hubbard RA, Miglioretti DL, Munsell MF, Trentham-Dietz A, van Ravesteyn NT, Tosteson ANA, Mandelblatt JS. Benefits, harms and costs for breast cancer screening in the US following implementation of digital mammography. *J Natl Cancer Inst.* 2014;106(4): dju092. doi:10.1093/jnci/dju092. PMC4067109.
163. *Wirtz HS, Boudreau DM, Gralow JR, Barlow WE, Gray SL, Bowles EJA, **Buist DSM**. Factors associated with long-term adherence to surveillance mammography recommendations among breast cancer survivors. *Breast Cancer Res Treat.* 2014 Feb;143(3):541-50. PMC3935518.
164. Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJA, Fujii M, **Buist DSM**. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. *Breast Cancer Res Treat.* 2014 Apr;144(2):405-16. doi: 10.1007/s10549-014-2870-5. PMC3988288.
165. Onega T, Weiss J, Kerlikowske K, Wernli K, **Buist DS**, Henderson LM, Goodrich M, Alford-Teaster J, Virnig B, Tosteson AN, DeMartini W, Hubbard R. The influence of race/ethnicity and place of service on breast reconstruction for Medicare beneficiaries with mastectomy. *Springerplus.* 2014 Aug;3:416. doi: 10.1186/2193-1801-3-416. PMC4137047.
166. Onega T, Hubbard R, Hill D, Lee C, Haas JS, Carlos HA, Alford-Teaster J, Bogart A, DeMartini WB, Kerlikowske K, Virnig BA, **Buist DSM**, Henderson L, Tosteson A. Geographic access to breast imaging for U.S. women. *J Am Coll Radiol.* 2014 Sep;11(9):874-82. doi: 10.1016/j.jacr.2014.03.022. doi: 10.1016/j.jacr.2014.03.022. PMC4156905.
167. **Buist DSM**, Anderson ML, Smith RA, Carney PA, Miglioretti DL, Monsees BS, Sickles EA, Taplin SH, Geller BM, Yankaskas BC, Onega TL. Effect of radiologists' diagnostic work-up volume on interpretive performance. *Radiology.* 2014 Nov;273(2):351-64. doi: 10.1148/radiol.14132806. PMC4334307.
168. Jordan JH, Thwin SS, Lash TL, **Buist DSM**, Field TS, Haque R, Pawloski PA, Peterson HV, Prout MN, Quinn VP, Yood MU, Silliman RA, Geiger AM. Incident comorbidities and all-cause mortality among five-year survivors of stage I and II breast cancer diagnosed at age 65 or older: a prospective matched cohort study. *Breast Cancer Res Treat.* 2014; 146:401-409. doi: 10.1007/s10549-014-3021-8. PMC4506645.
169. *Beaber EF, **Buist DSM**, Barlow WE, Malone KE, Reed SD, Li CI. Recent oral contraceptive use by formulation and breast cancer risk among women 20-49 years of age. *Cancer Res.* 2014 Aug;74(15):4078-89. doi: 10.1158/0008-5472.CAN-13-3400. PMC4154499.
170. Andersen MR, Thorpe J, **Buist DSM**, Beatty JD, Watabayashi K, Hanson N, Resta R, Chubak J, Urban N. Cancer risk awareness and concern among women with a family history of breast or ovarian cancer. *Behav Med.* 2016 Jan-Mar;42(1):18-28. doi: 10.1080/08964289.2014.947234. PMC4469617.
171. Owens CL, **Buist DSM**, Peterson D, Kamineni A, Weinmann S, Ross T, Williams AE, Stark A, Adams KF, Doubeni CA, Field TS. Follow-up and clinical significance of

- unsatisfactory liquid-based Papanicolaou tests. *Cancer Cytopathol.* 2015 Jan;123(1):59-65. doi: 10.1002/cncy.21490. PMC4356524.
172. Gao H, Bowles EJA, Carrell D, **Buist DSM**. Using natural language processing to extract mammographic findings. *J Biomed Inform.* 2015 Apr;54:77-84. doi: 10.1016/j.jbi.2015.01.010. PMC4408241.
 173. Loggers ET, Gao H, Gold LS, Kessler L, Etzioni R, **Buist DSM**. Predictors of preoperative MRI for breast cancer: differences by data source. *J Comp Eff Res.* 2015 May 11:1-12. PMC4641841.
 174. Gard CC, Aiello Bowles EJ, Miglioretti DL, Taplin SH, Rutter CM. Misclassification of Breast Imaging Reporting and Data System (BI-RADS) mammographic density and implications for breast density reporting legislation. *Breast J.* 2015 Sep-Oct;21(5):481-9. PMC4558212.
 175. Jackson SL, Abraham L, Miglioretti DL, **Buist DS**, Kerlikowske K, Onega T, Carney PA, Sickles EA, Elmore JG. Patient and radiologist characteristics associated with accuracy of two types of diagnostic mammograms. *AJR Am J Roentgenol.* 2015 Aug;205(2):456-63. doi: 10.2214/AJR.14.13672. PMC4809354.
 176. Lee JM, **Buist DSM**, Houssami N, Dowling EC, Halpern EF, Gazelle GS, Lehman CD, Henderson LM, Hubbard RA. Five-year risk of interval-invasive second breast cancer. *J Natl Cancer Inst.* 2015;107(7):pii: djv109. doi: 10.1093/jnci/djv109. PMC4651041
 177. Adams KF, Johnson EA, Chubak J, Kamineni A, Doubeni CA, **Buist DSM**, Williams AE, Weinmann S, Doria-Rose VP, Rutter CM. Development of an algorithm to classify colonoscopy indication from coded health care data. *EGEMS (Wash DC).* 2015 May;3(1):1171. doi: 10.13063/2327-9214.1171. PMC4537082.
 178. Kemp Jacobsen K, Abraham L, **Buist DS**, Hubbard RA, O'Meara ES, Sprague BL, Kerlikowske K, Vejborg I, Von Euler-Chelpin M, Njor SH. Comparison of cumulative false-positive risk of screening mammography in the United States and Denmark. *Cancer Epidemiol.* 2015 Aug;39(4):656-63. doi: PMC4871241.
 179. Weinmann S, Williams AE, Kamineni A, **Buist DSM**, Masterson EE, Stout NK, Stark A, Ross TR, Owens CL, Field TS, Doubeni CA. Cervical cancer screening and follow-up in 4 geographically diverse US health care systems, 1998 through 2007. *Cancer.* 2015 Sep;121(17):2976-83. doi: 10.1002/cncr.29445. PMC4545722.
 180. Chubak J, Onega T, Zhu W, **Buist DSM**, Hubbard RA. An electronic health record-based algorithm to ascertain the date of second breast cancer events. *Med Care.* 2017 Dec;55(12):e81-e87. PMC4592686.
 181. Allison KH, Abraham LA, Weaver DL, Tosteson AN, Nelson HD, Onega T, Geller BM, Kerlikowske K, Carney PA, Ichikawa LE, **Buist DS**, Elmore JG. Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: A report from the Breast Cancer Surveillance Consortium. *Cancer.* 2015 May 1;121(9):1369-78. doi: 10.1002/cncr.29199. PMC4419038.
 182. Falk RT, Dallal CM, Lacey JV, Bauer DC, **Buist DSM**, Cauley JA, Hue TF, LaCroix A, Tice JA, Pfeiffer RM, Xu X, Veenstra TD, Brinton LA, for the B-FIT Research Group. Estrogen metabolites are not associated with colorectal cancer risk in postmenopausal women. *Cancer Epidemiol Biomarkers Prev.* 2015 Sep;24(9):1419-22. doi: 10.1158/1055-9965.EPI-15-0541. PMC4560651.
 183. Wieneke AE, Bowles EJA, Cronkite D, Wernli KJ, Gao H, Carrell D, **Buist DSM**. Validation

- of natural language processing to extract breast cancer pathology procedures and results. *J Pathol Inform.* 2015 Jun;6:38. doi: 10.4103/2153-3539.159215. PMC4485196.
184. Onega T, Goldman LE, Walker RL, Miglioretti DL, **Buist DS**, Taplin S, Geller BM, Hill DA, Smith-Bindman R. Facility mammography volume in relation to breast cancer screening outcomes. *J Med Screen.* 2016 Mar;23(1):31-7. doi: 10.1177/0969141315595254. Epub 2015 Aug 11.
 185. Miglioretti DL, Zhu W, Kerlikowske K, Sprague BL, Onega T, **Buist DSM**, Henderson LM, Smith RA, for the Breast Cancer Surveillance Consortium. Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. *JAMA Oncol.* 2015 Nov;1(8):1069-77. doi: 10.1001/jamaoncol.2015.3084. PMC4644100.
 186. **Buist DSM**, Chang E, Handley M, Pardee R, Gundersen G, Cheadle A, Reid RJ. Primary care clinicians' perspectives on reducing low-value care in an integrated delivery system. *Perm J.* 2016 Winter; 20(1):41-6. PMC4732793.
 187. Lehman CD, Wellman RD, **Buist DSM**, Kerlikowske K, Tosteson ANA, Miglioretti DL, for the Breast Cancer Surveillance Consortium. Diagnostic accuracy of digital screening mammography with and without computer-aided detection. *JAMA Intern Med.* 2015 Nov;175(11):1828-37. doi: 10.1001/jamainternmed.2015.5231. PMC4836172.
 188. **Buist DSM**, Field TS, Banegas MP, Clancy HA, Doria-Rose P, Epstein MM, Greenlee RT, McDonald S, Nichols HB, Pawloski P, Kushi L. Training in the conduct of population-based multi-site and multi-disciplinary studies: the Cancer Research Network's Scholars program. *J Cancer Educ.* 2017 Jun;32(2):283-292. doi: 10.1007/s13187-015-0925-x. PMC4902776.
 189. Henderson LM, Weiss J, Hubbard RA, O'Donoghue C, DeMartini WB, **Buist DSM**, Kerlikowske K, Goodrich M, Virnig B, Tosteson ANA, Lehman CD, Onega T. Factors associated with preoperative magnetic resonance imaging use among Medicare beneficiaries with non-metastatic breast cancer. *Breast J.* 2016 Jan;22(1):24-34. doi: 10.1111/tbj.12522. PMC4718842.
 190. Chubak J, Bowles EJA, Yu O, **Buist DSM**, Fujii M, Boudreau DM. Breast cancer recurrence in relation in antidepressant use. *Cancer Causes Control.* 2016 Jan;27(1):125-36. doi: 10.1007/s10552-015-0689-y. PMC4913547.
 191. Dallal CM, Brinton L, Lacey J, Bauer J, **Buist DSM**, Cauley J, La Croix A, Hue T, Tice J, Pfeiffer R, Falk R, Veenstra T, Xu X. Estrogen metabolism and risk of postmenopausal endometrial and ovarian cancer: the B~FIT cohort. *Horm Cancer.* 2016 Feb;7(1):49-64. Epub 2016 Jan 4.
 192. Nichols HB, Bowles EJA, Islam J, Masziwa L, Strumer T, Tran DT, **Buist DSM**. Tamoxifen initiation after ductal carcinoma in situ. *Oncologist.* 2016 Feb;21(2):134-40. doi: 10.1634/theoncologist.2015-0310. PMC4746086.
 193. Elmore J, Cook AJ, Bogart A, Carney PA, Geller BM, Taplin S, **Buist DSM**, Onega TL, Lee CI, Miglioretti DL. Radiologists' interpretive skills in screening vs. diagnostic mammography: Are they related? *Clin Imag.* 2016;40(6):1096-1103. doi: 10.1016/j.clinimag.2016.06.014. PMC5159253.
 194. Goodrich ME, Weiss JE, Onega TL, Balch SL, **Buist DSM**, Kerlikowske K, Henderson LM, Hubbard RA, for the Breast Cancer Surveillance Consortium. The role of preoperative Magnetic Resonance Imaging in the assessment and surgical treatment of interval and screen-detected breast cancer in older women. *Breast J.* 2016 Nov;22(6):616-622. doi: 10.1111/tbj.12651. PMC5118086.

195. Bowles EAJ, Gao H, Brandzel S, Bradford SC, **Buist DSM**. Comparative effectiveness of two outreach strategies for cervical cancer screening. *Prev Med*. 2016 May;86:19-27. PMC4902104.
196. Farjah F, Halgrim S, **Buist DSM**, Gould MK, Zeliadt SB, Loggers ET, Carrell DS. An automated method for identifying individuals with a lung nodule can be feasibly implemented across health systems. *eGEMs*. 2016;4(1):1254. doi: 10.13063/2327-9214. PMC5013935.
197. Drescher CW, Beatty D, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, **Buist DSM**, Urban N. Effect of referral for genetic counseling on surgical prevention in women at high risk for ovarian cancer. *Cancer*. 2016 Jul; 122(22):3509-3518. doi: 10.1002/cncr.30190. PMC5253334.
198. Loggers ET, **Buist DSM**, Gold LS, Zeliadt A, Merrill RH, Etzioni R, Ramsey SD, Sullivan SD, Kessler L. Advanced imaging and receipt of guideline concordant care in women with early stage breast cancer. *Int J Breast Cancer*. 2016; 2016:2182985. doi: 10.1155/2016/2182985. PMC4976155.
199. Ozanne EM, Weiss JE, Onega T, DeMartini W, Kerlikowske K, **Buist DSM**, Henderson L, Hubbard RA, Goodrich M, Tosteson AN, Virnig BA, O'Donoghue C. Locoregional treatment of breast cancer in women with and without preoperative magnetic resonance imaging. *Am J Surg*. 2017 Jan;213(1):132-139.e2. doi: 10.1016/j.amjsurg.2016.03.014. PMC5708118.
200. Onega T, Weiss JE, **Buist DS**, Tosteson AN, Henderson LM, Kerlikowske K, Goodrich ME, O'Donoghue C, Wernli KJ, DeMartini WB, Virnig BA, Bennette CS, Hubbard RA. Breast MRI in the diagnostic and preoperative workup among Medicare Beneficiaries with breast cancer. *Med Care*. 2016 Jul;54(7):719-24. doi: 10.1097/MLR.0000000000000542. PMC5001851.
201. Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, **Buist DS**, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the US Preventive Services Task Force. *Ann Intern Med*. 2016 Jun;164(12):814-25. doi: 10.7326/M15-2117. Epub 2016 Apr 12.
202. Brandzel S, Chang E, Tuzzio L, Campbell C, Coronado N, Bowles E, Bradford SC, **Buist DSM**. Latina and African-American/Black women's perspectives on cancer screening and cancer screening reminders. *J Racial Ethn Health Disparities*. 2016 Nov. PMC5436953.
203. Parchman M, Henrikson N, Blasi P, **Buist DSM**, Penfold R, Austin B, Ganos E. Taking action on overuse: creating the culture for change. *Healthc (Amst)*. 2017 Dec;5(4):199-203. doi: 10.1016/j.hjdsi.2016.10.005. Epub 2016 Nov 10.
204. Onega T, Weiss J, Goodrich ME, Zhu W, DeMartini W, Kerlikowske K, Ozanne E, Tosteson A, Henderson L, **Buist DSM**, Wernli K, Herschorn S, Hotaling E, O'Donoghue C, Hubbard R. Relationship between preoperative breast MRI and surgical treatment of non-metastatic breast cancer. *J Surg Oncol*. 2017 Dec;116(8):1008-1015. PMC5760434.
205. Chang E, **Buist DSM**, Handley M, Pardee R, Gundersen G, Reid RJ. Physician service attribution methods for examining provision of low-value care. *eGEMs (Wash DC)*. 2016;4(1):Article 29. PMC5302861.
206. Wirtz H, Calip G, **Buist DSM**, Gralow J, Barlow W, Gray SL, Boudreau D. Evidence for detection bias by medication use in a cohort study of breast cancer survivors. *Am J Epidemiol*. 2017;185(8):661-72. PMC5394250.

207. Lehman C, Arao R, Sprague BL, Lee JM, **Buist DSM**, Kerlikowske K, Henderson LM, Onega T, Tosteson ANA, Rauscher GH, Miglioretti DL. National performance benchmarks for modern screening digital mammography: Update from the Breast Cancer Surveillance Consortium. *Radiology*. 2017 Apr;283(1):49-58. PMC5375631.
208. Ahern TP, Sprague BL, Bissel MC, Miglioretti DL, **Buist DSM**, Braithwaite D, Kerlikowske K. Family history of breast cancer, breast density, and breast cancer risk in a U.S. breast cancer screening population. *Cancer Epidemiol Biomarkers Prev*. 2017 Jun;26(6):938-944. PMC5457358.
209. Carter-Harris L, Brandzel S, Wernli KJ, Roth J, **Buist DSM**. A qualitative study exploring why individuals opt out of lung cancer screening. *Fam Pract* 2017; 34 (2): 239-244. PMC6279209.
210. Lee JM, Ichikawa L, Valencia E, Miglioretti DL, Wernli KJ, **Buist DSM**, Kerlikowske K, Henderson LM, Sprague BL, Onega T, Rauscher GH, Lehman CD. Performance benchmarks for screening breast MRI in community practice. *Radiology*. 2017 Oct;285(1):44-52. PMC5621720.
211. Miglioretti DL, Ichikawa L, **Buist DSM**, Carney PA, Geller B, Monsees B, Onega T, Rosenberg R, Sickles E, Yankaskas B, Kerlikowske K. Correlation between screening mammography interpretive performance on a test set and performance in clinical practice. *Acad Radiol*. 2017 Oct;24(10):1256-1264. PMC5591765.
212. Trister AD, **Buist DSM**, Lee CI. Will machine learning tip the balance in breast cancer screening? *JAMA Oncol*. May 2017;3(11): 1463-64. doi: jamanetwork/2017/cvpl70004.
213. Sprague BL, Arao R, Miglioretti DL, Henderson LM, **Buist DSM**, Onega T, Rauscher GH, Lee JM, Tosteson ANA, Kerlikowske K, Lehman CD for the Breast Cancer Surveillance Consortium. National performance benchmarks for modern diagnostic digital mammography: update from the Breast Cancer Surveillance Consortium. *Radiology*. 2017 Apr;283(1): 59-69. PMC5375630.
214. Brandzel SD, Aiello Bowles EJ, Wieneke A, Bradford SC, Kimbel K, Gao H, **Buist DSM**. Cancer screening reminders: addressing the spectrum of patient preferences. *Perm J*. 2017;21. PMC5638633.
215. **Buist DSM**, Gao H, Anderson ML, Onega T, Brandzel S, Rabelhofer MA, Bradford SC, Aiello Bowles EJ. Breast cancer screening outreach effectiveness: Mammogram-specific reminders vs. comprehensive preventive services birthday letters. *Prev Med*. 2017 Sep;102:49-58. PMC5638650.
216. Shiyambola OO, Arao RF, Miglioretti DL, Sprague BL, Hampton JM, Stout NK, Kerlikowske K, Braithwaite D, **Buist DSM**, Egan KM, Newcomb PA, Trentham-Dietz A. Emerging trends in family history of breast cancer and associated risk. *Cancer Epidemiol Biomarkers Prev*. 2017 Dec;26(12):1753-1760. PMC5712247.
217. Winer RL, Tiro JA, Miglioretti DL, Thayer C, Beatty T, Lin J, Gao G, Kimbel K, **Buist DSM**. Rationale and design of the HOME trial: a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. *Contemp Clin Trials*. 2018 Jan;64:77-87. PMC5742021.
218. **Buist DSM**, Abraham L, Lee CI, Lee JM, Lehman C, O'Meara ES, Stout NK, Henderson LM, Hill D, Wernli KJ, Haas JS, Tosteson ANA, Kerlikowske K, Onega T. Breast biopsy intensity and findings following breast cancer screening in women with and without a personal history of breast cancer. *JAMA Internal Med*. 2018 Apr 1;178(4):458-468. doi: 10.

1001/jamainternmed.2017.8549. PMC5876894.

219. Braithwaite D, Miglioretti DL, Zhu W, Demb J, Trentham-Dietz A, Sprague B, Tice JA, Onega T, Henderson LM, **Buist DSM**, Ziv E, Walter LC, Kerlikowske K, for the Breast Cancer Surveillance Consortium. Family history and breast cancer risk among older women in the Breast Cancer Surveillance Consortium Cohort. *JAMA Intern Med.* 2018 Apr 1;178(4):494-501. doi: 10.1001/jamainternmed.2017.8642. PMC5876845.
220. Onega T, Zhu W, Weiss JE, Goodrich M, Tosteson ANA, DeMartini W, Virnig BA, Henderson LM, **Buist DSM**, Wernli KJ, Kerlikowske K, Hubbard RA. Preoperative breast MRI and mortality in older women with breast cancer. *Breast Cancer Res Treat.* 2018 Jul;170(1):149-157. doi: 10.1007/s10549-018-4732-z. PMC5994182.
221. Brentnall AR, Cuzick J, **Buist DSM**, Bowles EJA. Long-term accuracy of breast cancer risk assessment combining classic risk factors and breast density. *JAMA Oncol.* 2018 Sep 1;4(9):e180174. doi:10.1001/jamaoncol.2018.0174. Epub 2018 Sep 13. PMC6143016.
222. Chang E, **Buist DSM**, Handley M, Johnson E, Fuller S, Pardee R, Gundersen G, Reid RJ. Primary care physician resource use changes associated with feedback reports. *Am J Manag Care.* 2018 Oct 8. 24(10):455-461. [Epub ahead of print]
223. Roth J, Brandzel S, Carter-Harris L, **Buist DSM**, Wernli KJ. A qualitative study exploring patient motivations for screening for lung cancer. *PLoS One.* 2018 Jul 5;13(7):e0196758. doi: 10.1371/journal.pone.0196758. eCollection 2018. PMC6033377.
224. Lee JM, Abraham L, Lam DL, **Buist DSM**, Kerlikowske K, Miglioretti DL, Houssami N, Lehman CD, Henderson LM, Hubbard RA. Cumulative risk distribution for interval invasive second breast cancers after negative surveillance mammography. *J Clin Oncol.* 2018 Jul 10;36(20):2070-2077. doi: 10.1200/JCO.2017.76.8267. PMC6036621.
225. Tiro J, Betts AC, Kimbel K, **Buist DSM**, Mao C, Gao H, Shulman L, Malone C, Beatty T, Lin J, Thayer C, Miglioretti DL, Winer RL. Understanding the patient's perspective and information needs following a positive home human papillomavirus self-sampling kit result. *J Womens Health (Larchmt).* 2019 Mar;28(3):384-392. doi: 10.1089/jwh.2018.7070. PMC6444912.
226. Knerr S, Bowles EA, Leppig K, Gao H, **Buist DSM**, Wernli KJ. Trends in *BRCA* genetic test utilization in an integrated health care system, 2005-2015. *J Natl Cancer Inst.* 2019 Feb 8. doi: 10.1093/jnci/djz008. [Epub ahead of print]
227. Miglioretti DL, Abraham L, Lee CI, **Buist DSM**, Herschorn S, Sprague BL, Henderson LM, Tosteson ANA, Kerlikowske K; for the Breast Cancer Surveillance Consortium. Digital Breast Tomosynthesis: Radiologist Learning Curve. *Radiology.* 2019 Apr;291(1):34-42. doi: 10.1148/radiol.2019182305. PMC6438358.
228. Arasu VA, Miglioretti DL, Sprague BL, Alsheik NH, **Buist DSM**, Henderson LM, Herschorn SD, Lee JM, Onega T, Rauscher GH, Wernli KJ, Lehman CD, Kerlikowske K. Population-Based Assessment of the Association between MRI Background Parenchymal Enhancement and Future Primary Breast Cancer Risk. *J Clin Oncol.* 2019 Apr;37(12):954-963. doi: 10.1200/JCO.18.00378. PMC6494266.
229. Doria-Rose VP, Greenlee RT, **Buist DSM**, Miglioretti DL, Corley DA, Brown J, Clancy HA, Tuzzio L, Moy L, Hornbrook MC, Brown ML, Ritzwoller DP, Kushi LH, Greene SM. Collaborating on Data, Science, and Infrastructure: The 20-Year Journey of the Cancer Research Network. *eGEMS (Wash DC).* 2019 Mar;7(1):7. doi: 10.5334/egems.273. PMC6450242.

230. Wernli KJ, Ichikawa L, Kerlikowske K, **Buist DSM**, Brandzel SD, Bush M, Johnson D, Henderson LM, Nekhlyudov L, Onega T, Sprague B, Lee J, Lehman C, Miglioretti D. Surveillance Breast MRI and Mammography: Comparison in Women with a Personal History of Breast Cancer. *Radiology*. 2019 Jun;182475. doi: 10.1148/radiol.2019182475. [Epub ahead of print].
231. Kerlikowske K, Sprague BL, Tosteson ANA, Wernli KJ, Rauscher GH, Johnson D, Buist DSM, Onega T, Henderson LM, O'Meara ES, Miglioretti DL. Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging. *JAMA Intern Med*. 2019 Jul. doi:10.1001/jamainternmed.2019.1758. [Epub ahead of print]
232. Sun L, Brentnall A, Patel S, **Buist DSM**, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Duffy S, Cuzick J, dos-Santos-Silva I, Sadique Z, Yang L, Legood R, Manchanda R. Should we offer multi-gene testing to all patients with breast cancer: a cost-effectiveness analysis. In press: *JAMA Oncol*.
233. Henderson LM, Ichikawa L, **Buist DSM**, Lee J, Bush M, Johnson D, Onega T, Nekhlyudov L, Kerlikowske K, Miglioretti DL, Sprague BL, Wernli KJ. Patterns of Breast Imaging Use among Women with a Personal History of Breast Cancer. In press: *J Gen Intern Med*.
234. **Buist DSM**, Tiro JA, Thayer C, Beatty T, Miglioretti DL, Lin J, Winer RL. Improving the promise of embedded pragmatic trials: surmountable barriers encountered in an evaluation of home-based HPV self-sampling to increase cervical cancer screening in overdue women. *Contemp Clin Trials Commun*. 2019 Sep;15:100413. doi: 10.1016/j.conctc.2019.100413.
235. Eavey J, Ramaprasan A, Abraham L, **Buist DSM**. Caveat emptor: comorbidity index score increases due to coding artifacts in chronic kidney disease and renal failure. In press: *Epidemiology*.

UNDER REVIEW

1. Lee C, Houssami N, Elmore JG, **Buist DSM**. Pathways to Breast Cancer Screening Artificial Intelligence Algorithm Validation. Under review: *Breast*.
2. Malone C, Barnabas RV, Buist DSM, Tiro JA, Winer RL. Cost-Effectiveness Studies of HPV Self-Sampling: A Systematic Review. Under review: *Prev Med*.
3. Winer RL, Lin J, Tiro JA, Miglioretti DL, Beatty T, Gao H, Kimbel K, Thayer C, **Buist DSM**. Effect of Mailed HPV Kits vs Usual Care Reminders on Cervical Cancer Screening Uptake, Precancer Detection and Treatment in a US Healthcare System: A Pragmatic Randomized Trial. Under review: *JAMA*.
4. Malone C, Tiro JA, **Buist DSM**, Beatty T, Lin J, Kimbel K, Gao H, Thayer C, Miglioretti DL, Winer RL. Experiences and reactions among underscreened women who did and did not return unsolicited mailed HPV self-sampling kits for cervical cancer screening. Under review: *J Med Screen*.
5. Schifferdecker KE, Tosteson ANA, Kaplan C, Kerlikowske K, **Buist DSM**, Henderson LM, Johnson D, Jaworski J, Jackson-Nefertiti G, Ehrlich K, Marsh K, Vu L, Onega T, Wernli KJ. Knowledge and perception of breast density, screening mammography, and supplemental screening: In search of "informed". Submitted: *J Gen Intern Med*.

EDITORIALS AND LETTERS TO THE EDITOR

1. Mandelblatt J, **Buist DS**. The elusive goal of maintaining population cancer screening: it is time for a new paradigm. *J Natl Cancer Inst*. 2010 Jul 21;102(14):998-9. Epub 2010 Jun 29. (Editorial)
2. Hubbard R, Kerlikowske K, **Buist DSM**, Yankaskas B for the Breast Cancer Surveillance Consortium. Evaluation of breast cancer screening strategies must be based on comparison of harms and benefits [Letter]. *AJR Am J Roentgenol*. 2011 Oct;197(4):W793.
3. Kerlikowske K, **Buist DSM**, Walker R. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. *J Natl Cancer Inst*. 2007;99:6-1817.
4. Gao H, **Buist DSM**, Lash TL, Bosco JL, Swihart B. Lasagna plots made in different (statistical) ovens. *Epidemiology*. 2012 Nov;23(6):934.
5. Chubak J, Yu O, **Buist DSM**, Wirtz HS, Boudreau DM. Time scale in follow-up studies: considering disease prognosis. *Epidemiology*. 2013 Jul;24(4):628-9.
6. Carrell DS, Halgrim S, Tran DT, **Buist DS**, Chubak J, Chapman WW, Savova G. Carrell et al. respond to "Observational research and the EHR". *Am J Epidemiol*. 2014;179(6):762-3.
7. Houssami N, Lee CI, Buist DSM, Tao D. Artificial intelligence for breast cancer screening: Opportunity or hype? *Breast*. 2017 Dec;36:31-33. doi:10.1016/j.breast.2017.09.003. Epub 2017 Sep 20.
8. Brentnall AR, **Buist DSM**, Cuzick J. Long-term accuracy of breast cancer risk assessment combining classic risk factors and breast density – Authors' reply. In press: *JAMA Oncol*.
9. Brentnall AR, **Buist DSM**, Cuzick J. Competing Risks for a Diagnosis of Invasive Breast Cancer—Reply. *JAMA Oncol*. 2018 Nov. doi:10.1001/jamaoncol.2018.5102.
10. Habel LA, **Buist DSM**. Re: Cancer outcomes in DCIS patients without locoregional treatment. *J Natl Cancer Inst*. 2019 Jun. doi: 10.1093/jnci/djz118. [Epub ahead of print]

OTHER PUBLICATIONS

1. **Buist DSM**, LaCroix AZ, Newton KM, Keenan NL. Long-term HRT users. *Menopause Digest*. 2000;12:210-21.
2. Chang S, **Buist DSM**, Reid M, Terry MB, Trentham-Dietz A. The characteristics and training of professionals in cancer prevention and control: a survey of the American Society for Preventive Oncology (ASPO). *Cancer Epidemiol Biomarkers Prev*. 2004;13:1094-8.
3. **Buist DSM**, Kanetsky PA, Studts JL, Li L, Terry MB, Trentham-Dietz A, Chang S. Recruiting and training leadership through professional societies: a report from the American Society of Preventive Oncology Junior Career Development Interest Group. *Cancer Epidemiol Biomarkers Prev*. 2006;15:1422-24.
4. Trentham-Dietz A, **Buist DSM**, Kelley KM, Jacobson JS, Paskett E for the ASPO Survivorship Interest Group. Charting a strategic direction for the American Society of Preventive Oncology's Survivorship Interest Group. *Cancer Epidemiol Biomarkers Prev*. 2007;16:1912-3.

5. Geiger AM, Strom SS, Demark-Wahnefried W, **Buist DSM**. Strategies to maximize the competitiveness of cancer survivorship grant applications. *Cancer Epidemiol Biomarkers Prev*. 2008;17 2899-2900.
6. Hudson SV, Chubak J, Coups EJ, Blake-Gumbs L, Jacobsen PB, Neugut AI, **Buist DSM**. Identifying key questions to advance research and practice in cancer survivorship follow-up care: a report from the ASPO Survivorship Interest Group. *Cancer Epidemiol Biomarkers Prev*. 2009 Jul;18(7):2152-4.
7. Cook AJ, Onega TL, Shui X, Kirilin BA, **Buist D**. PS2-36: Influence of travel time on the receipt of surveillance mammograms for women with history of breast cancer. *Clin Med Res*. 2010 March; 8(1): 35. PMC2842362.
8. Yankaskas B, Haneuse S, Kapp JM, Geller BM, **Buist DSM**. Response to Eisinger. *J Natl Cancer Inst*. 2010 Nov 17;102(22):1742; author reply 1742, 1742-3. Epub 2010 Oct 21.
9. Palesh O, Demark-Wahnefried W, Mustian K, Minasian L, Rowland J, Sprod L, Janelsins M, Peppone L, Sloan J, Engquist KB, Jones L, **Buist D**, Paskett ED. Conducting cancer control and survivorship research via cooperative groups: a report from the American Society of Preventive Oncology. *Cancer Epidemiol Biomarkers Prev*. 2011 May;20(5):1050-5. Epub 2011 Apr 18. PMC3124556.
10. Nichols HB, Sprague BL, **Buist DS**, Erwin DO, Leach CR, Patrick H. Careers in cancer prevention: what you may not see from inside your academic department-a report from the American Society of Preventive Oncology's Junior Members Interest Group. *Cancer Epidemiol Biomarkers Prev*. 2012 Aug;21(8):1393-5. Epub 2012 Jun 13.
11. **Buist DSM**, Tuzzio L, Greenlee R, Field T, Williams A, Weinmann S, Stout N, Kamineni A, Doubeni C. PS1-33: Cancer screening guideline development, implementation and dissemination: connection points for researchers and health care delivery systems for comparative effectiveness research. *Clin Med Res*. 2012 Aug;10(3):157. PMC342132.
12. Chubak J, Kamineni A, **Buist DSM**, Anderson ML, Whitlock EP. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force.; Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. Report No.: 15-05228-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.
13. Wernli KJ, Brandzel SD, **Buist DSM**, Bush M, DeMartini W, Ichikawa L, Haas C, Henderson LM, Johnson D, Kerlikowske K, McColgin D, Miglioretti DL, Nekhlyudov L, Onega T, Rosenberg DE. Is Breast MRI Better at Finding Second Breast Cancers than Mammograms Alone for Breast Cancer Survivors? Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2019.
<https://doi.org/10.25302/5.2019.CE.13046656>.

BOOK CHAPTERS

Newton KM, LaCroix AZ, **Buist DSM**. Overview of Risk Factors for Cardiovascular Disease. Chapter 59 in *Women and Health*. MB Goldman and MC Hatch (eds). Academic Press 1999.

PUBLISHED POLICY BRIEFS

Buist DSM, Collado M. Promoting the Appropriate Use of Health Care Services: Research and Policy Priorities. June 2014. Sponsored by American Board of Internal Medicine Foundation and AcademyHealth.

SELECTED PUBLISHED ABSTRACTS

1. **Buist DSM**, LaCroix AZ, Newton KM. Long-term hormone replacement therapy (HRT) users: Are they different and why do they Persist? *Am J Epidemiol*. 1997;145:S1.
2. Newton KM, LaCroix AZ, **Buist DSM**. Do providers encourage HRT use for women at high risk of coronary disease? A focus on attitudes and prescribing behaviors. *Circulation (suppl)*. 1997;96:131.
3. LaCroix AZ, Newton KM, **Buist DSM**, Keenan NL, Anderson LA. What factors account for differences in HRT prescribing by healthcare providers in a health maintenance organization? The EnPower Provider Survey. *Menopause*. 1997;4:262.
4. Anderson LA, Caplan LS, **Buist DSM**, Newton KM, Curry S, LaCroix AZ. Counseling about HRT: Perceived barriers and recommendations among primary care providers. *Menopause*. 1997;4:263.
5. Newton KM, Anderson LA, LaCroix AZ, **Buist DSM**, Keenan NL. Healthcare provider characteristics and encouragement to use HRT: the EnPower provider survey. *Menopause*. 1997;4:263.
6. Newton KM, LaCroix AZ, **Buist DSM**, Neenan NL. The use of alternative and complementary medicine by women enrolled in an HMO setting. *Menopause*. 1998;4:263.
7. **Buist DSM**, LaCroix AZ, Barlow WE, White E, Cauley JA, Bauer DC, Weiss NS. Bone mineral density, endogenous hormones, and risk of postmenopausal breast cancer. *Cancer Epidemiol Biomarkers Prev*. 2000;9:235.
8. **Buist DSM**, LaCroix AZ, Barlow WE, White E, Cauley JA, Bauer DC, Weiss NS. Bone mineral density, endogenous hormones, and risk of postmenopausal breast cancer. *Am J Epidemiol*. 2000;151:S31.
9. Park A, **Buist D**, Taplin S. Mammography participation among low-income women in a staff model HMO. *Cancer Epidemiol Biomarker Prev*. 2002;11:1173s.
10. Fuller S, Pardee R, Chang E, Gundersen G, Reid RJ, Handley MR, **Buist DS**. Choosing Wisely: Using the EHR to identify variability in provider ordering behavior for high-end imaging of the head. *J Patient-Centered Res Rev*. 2015;2:96.
11. **Buist DS**, Handley MR, Chang E, Pardee R, Gundersen G, Cheadle A, Reid RJ. Primary care provider perspectives on reducing low-value care. *J Patient-Centered Res Rev*. 2015;2:124

COMPLETED RESEARCH GRANTS (as Principal Investigator or Co-Investigator)

1. Co-Investigator: Bone Density, Endogenous Hormones & Breast Cancer Risk, 1997-1999. (Principal Investigator: Andrea LaCroix). Dissertation R03 Funded by the National Cancer Institute. GH direct costs: \$49,999. % Effort: 35%.
2. Co-Investigator (Site Principal Investigator): Alendronate and GI Bleeding, Perforation, and Ulcers - a Collaborative Study in Nine HMO's, 1997-1999. Funded by Merck & Co. Inc (Principal Investigator: Richard Platt). GH direct costs: \$74,455. % Effort: 15%.
3. Co-Investigator: A Study to Compare the Effectiveness of Two Risk Based Osteoporosis Prescreening Instruments. Funded by Merck & Co. Inc. 1997-2002. (Principal Investigator,

Andrea LaCroix). Direct costs: \$450,064. % Effort: 20%.

4. Co-Investigator (Site Principal Investigator): Epidemiologic Study of the Incidence of Gastric and Duodenal Perforations, Ulcers and Bleeds in Women with Osteoporosis, 1998-1999. Funded by Merck & Co. Inc (Principal Investigator: Richard Platt). GH direct costs: \$40,331. % Effort: 15%.
5. Co-Investigator (Site Principal Investigator): Bone Mineral Density & Subsequent Cancer Risk, MQ015453. Funded by the National Cancer Institute 2000-2004. (Principal Investigator, Douglas Bauer). GH direct costs: \$64,771. % Effort: 10%.
6. Principal Investigator: Breast Cancer Surveillance in a Defined Population. CA63731. U01 Funded by the National Cancer Institute, 2000-2005. Direct costs: \$3,320,156. % Effort: 25%
7. Co-Investigator (Site Principal Investigator). Modeling US Prostate Cancer Trends: PSA, Treatment and Race. CA088160 Funded by National Cancer Institute. (Principal Investigator Ruth Etzioni.) 2000-2010 GH Direct Costs: \$44,861. % Effort: 4%
8. Co-Investigator (*Project leader*): HRT Initiation and Cessation Following Results from the Women's Health Initiative. CA79689. Funded by the National Cancer Institute (supplement to U19) (Principal Investigator, Edward Wagner), 2002-2004. Direct costs: \$150,418. % Effort: 10%.
9. Principal Investigator: Optimizing Breast Cancer Outcomes: BMI, Tumor Markers, and Quality of Care. Clinical Research Training Grant 03-024-01-CCE. Funded by the American Cancer Society, 2003-2006. Direct costs: \$375,432. % Effort: 42%.
10. Co-Investigator (Site Principal Investigator): Breast Cancer Treatment Effectiveness in Older Women. CA093772. R01 funded by the National Cancer Institute (Principal Investigator, Rebecca Silliman), 2003-2007. GH direct costs: \$312,666. % Effort: 17%.
11. Co-Investigator. The HMO Cancer Research Network (CRN) – Infrastructure. CA79689. U19 Funded by the National Cancer Institute. 2003-2007. (Principal Investigator: Edward Wagner). GH Direct costs: \$8,065,123. % Effort 5% (Year 4 only)
12. Principal Investigator: A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of HRT on Mammography Assessments and Breast Density. DOD17-03-1-0447. Idea Award funded by the Department of Defense, 2003-2008. Direct costs: \$1,041,096. % Effort: 17%.
13. *Co-Investigator: Statin Use and the Risk of Site-Specific Cancers. CA108357. R03 Funded by the National Cancer Institute. (Principal Investigator, Denise Boudreau). 2004-2007. GH direct costs: \$100,000. % Effort: 3%
14. Co-Investigator (Site Principal Investigator): Gene copy number changes in breast cancer survival. CA098415. R01 Funded by the National Cancer Institute (Principal Investigator, Peggy Porter). 2004-2010. Direct costs: \$1,445,019. % Effort 4%.
15. Co-Investigator. Understanding Variability in Community Mammography. CA107623. R01 Funded by the National Cancer Institute and Agency for Healthcare Quality. (Principal Investigator, Joann Elmore). 2004-2010. GH Direct costs: \$691,971. % Effort 5%.
16. Co-Investigator (Site Principal Investigator): Effects of Aspirin on Biomarkers of Breast Cancer Risk. P50 CA083636. Funded Avon Foundation Breast Cancer Prevention Research

- Initiative 2004-2006. (Principal Investigator: Nicole Urban). GH Direct Costs: \$286,843. % Effort: 5%.
17. Principal Investigator: Breast Cancer Surveillance in a Defined Population bridge funding. CA63731. U01 Funded by the National Cancer Institute, 4/2005-7/2005. Direct costs: \$67,659. % Effort: 15%.
 18. Co-Investigator (*Project leader*): Diffusion of hormone therapy between 1999-2003. CA79689. Funded by the National Cancer Institute (supplement to U19) (Principal Investigator, Edward Wagner), 2005-2006. Direct costs: \$89,241. % Effort: 5%.
 19. Principal Investigator: Breast Cancer Surveillance in a Defined Population. CA063731. U01 Funded by the National Cancer Institute, 2005-2011. Direct costs: \$1,310,037. % Effort: 15%.
 20. Co-Investigator (Site Principal Investigator): Is Stroke a Late Effect of Chemotherapy? R01 CA121303 funded by the National Cancer Institute (Principal Investigator: Ann Geiger), 2006. GH direct costs: \$19,648. % Effort: 5%.
 21. Principal Investigator. A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of HRT on Mammography Assessments and Breast Density-Supplement. DOD17-03-1-0447. Idea Award funded by the Department of Defense, 2006-2008. Direct Costs: \$226,000 % Effort: 17%
 22. Principal Investigator. Assessing and Improving Radiologists' Mammography Interpretive Skills. CA063731. U01 Funded by the National Cancer Institute. 2006-2007. GH Direct Costs: \$74,658. % Effort: 17%.
 23. Principal Investigator. Assessing and Improving Radiologist's Mammography Interpretive Skills. Funded by the American Cancer Society SIR-SG-07-271-01. 2006-2009. Group Health* direct costs: \$568,800. % Effort: 15%.
 24. Principal Investigator: Breast Cancer Surveillance in a Defined Population Administrative Supplement. CA063731. U01 Funded by the National Cancer Institute, 2006-2010. Direct costs: \$63,585. % Effort: 10%.
 25. Principal Investigator: Breast Cancer Surveillance in a Defined Population Administrative Supplement. CA063731. U01 Funded by the National Cancer Institute, 2007-2008. Direct costs: \$15,625. % Effort: 10% (effort concurrent with CA063731).
 26. Co-Investigator (Site Principal Investigator): Total Xenoestrogen Body Burden in Relation to Mammographic Density, A Marker of Breast Cancer Risk. X81XWH-07-1-0522. Funded by Department of Defense. (Principal Investigator, Amy Trentham). 2007-2009. GH Direct costs: \$49,451. % Effort 7%.
 27. Co-Investigator (Site Principal Investigator): Prevention of Ovarian Cancer in Women Participating in Mammography. 5R18DP001142 Funded by the Centers for Disease Control and Prevention. (Principal Investigator: Nicole Urban). 2007-2011. GH direct costs: \$78,125. % Effort 5%.
 28. Co-Investigator. Building a Pharmacovigilance Population-based Laboratory - CRN3 Administrative Supplement. CA079689. Funded by National Cancer Society. (Principal Investigator Ed Wagner.) 2008-2010. GH Direct Costs: \$1,387,346. % Effort: 6%.
 29. Co-Investigator. Statistical Coordinating Center for the Breast Cancer Surveillance Consortium - APRC Supplement. CA086076. U01. Funded by National Cancer Institute.

- (Principal Investigator: Diana Miglioretti) 2009-2011. GH Direct Costs: \$403,485. % Effort: 5%.
30. Co-Investigator. Institutional and Clinical Translational Science Award Comparative Effectiveness Research Workforce Development. RR025014. U54. Funded by National Center for Research Resources. (Principal Investigator: Mary L. Dsis.) 2010-2011. % Effort: 5%.
 31. *Co-Investigator. Commonly used medications and breast cancer outcomes (COMBO). ARRA Supplement. CA120562 R01 Funded by the National Cancer Institute. (Principal Investigator, Denise Boudreau). 2009-2011. GH Direct costs: \$199,721. % Effort: 6%.
 32. Co-Investigator. The HMO Cancer Research Network (CRN) – Infrastructure. CA79689. U19 Funded by the National Cancer Institute. (Principal Investigator: Edward Wagner). 2007-2012. Total Direct costs: \$14,821,127. % Effort 11%.
 33. *Co-Investigator. CRN Pilot: Integrating Cost Communication into Cancer Care. Pilot. Cancer Research Network U19 CA079689. (Principal Investigator: Ed Wagner). 2011-2012. GH Direct Costs: \$80,000 % Effort: 5%.
 34. *Principal Investigator. Oral Contraceptive Use by Formulation and Breast Cancer Risk by Subtype. CA141485. R03. Funded by National Cancer Institute. 2009-2012. GH Direct Costs: \$100,000. % Effort: 2%.
 35. Co-Principal Investigator. Assessing Diagnostics and Variations for Innovative Comparative Effectiveness Research in Cancer (ADVICE). CA1484331. RC2. Funded by National Cancer Institute. (Co-Principal Investigators: Larry Kessler, Sean Sullivan Scott Ramsey) 2009-2012. Total Direct Costs: \$1,990,436. % Effort 20%.
 36. Co-Principal Investigator. SEARCH: Cancer Screening Effectiveness And Research in Community-based Healthcare. RC2CA148576. Funded by National Cancer Institute. (Co-Principal Investigator: Chyke Doubeni) 2009-2012. Total Direct Costs: \$3,195,294. % Effort: 25%.
 37. Co-Principal Investigator. Comparative Effectiveness of Breast Cancer Imaging Strategies in Community Practice: BCS Project. RC2CA148577. Funded by National Cancer Institute. (Co-Principal Investigators: Diana Miglioretti, Karla Kerlikowske, Bonnie Yankaskas, Berta Geller, Anna Tosteson, Jeanne Mandelblatt). 2009-2012. Total Direct Costs: \$3,333,692. % Effort: 12.5%
 38. *Co-Investigator. Algorithms to Identify Second Breast Cancer Events from Electronic Data. R21CA143242. Funded by National Cancer Institute. (Principal Investigator Jessica Chubak) 2010-2012. Total Direct Costs: \$270,259. % Effort: 3%.
 39. Principal Investigator. Assessing and Improving Radiologists' Mammography Interpretive Skills. Supplement Funded by American Cancer Society. SIR-SG-07-271-01 2009-2012. Direct Costs: \$106,745. % Effort: 25%.
 40. *Co-Investigator. Commonly used medications and breast cancer outcomes (COMBO). R01 CA120562. Funded by the National Cancer Institute. (Principal Investigator, Denise Boudreau). 2006-2012. GH Direct costs: \$1,545,431. % Effort: 20%
 41. Co-Investigator (Site Principal Investigator.) Long-Term Survivorship in Older Women with Early Stage Breast Cancer (BOWII). R01 CA0937772. Funded by National Cancer Institute.

- (Principal Investigator Rebecca Silliman) 2008-2012. GH Direct Costs: \$306,354. % Effort: 10%.
42. *Co-Investigator. System-level Tools for Helping Doctors and Patients Know Cancer Treatment Costs in Real-Time. Funded by Group Health Research Institute* Development Funds. (Principal Investigator: Nora Henrikson.) 2012. GH Direct Costs: \$ 49,523. % Effort: 5%.
 43. *Mentor. Mentored Clinical Scientist Comparative Effectiveness Career Development Program at the University of Washington. K12 HS019482 Training Grant application. Funded by Agency for Health Care Quality. (Principal Investigator: Sean Sullivan) 2010-2013 GH Direct Costs: \$206,797. % Effort: 2%.
 44. Principal Investigator. Effectiveness of Healthcare System Outreach for Breast Cancer Screening. RSGI-II-I 00-0 I-CPHPS. Funded by American Cancer Society. 2011-2014. GH Direct Costs: \$391,665. % Effort: 20%.
 45. Co-Investigator (Site Principal Investigator) . Breast and Ovary Cancer Clinical Validation Center: Administrative Supplement. U01 CA152637. Funded by National Cancer Institute. (Principal Investigator: Christopher Li.) 2012-2014. GH Direct Costs: \$44,300. % Effort: 6%.
 46. Co-Investigator (Site Principal Investigator). Comparative Modeling: Informing Breast Cancer Control Practice & Policy - Administrative Supplement. National Cancer Institute. (Principal Investigator: Jeanne Mandelblatt). 2013-2014. GH Direct Costs: \$19,764. % Effort: 2%.
 47. Co-Principal Investigator. Reducing Low Value Care. Foundation Grant. Funded by Group Health Foundation. 2012-2015. GH Direct Costs: \$200,000. %Effort: 10%.
 48. Co-Investigator. Kaiser Permanente and Research Affiliates Evidence Based Practice Center. Task Order #4, USPSTF Systematic Review. HSA290201200015i (Principal Investigator: Evelyn Whitlock). Agency for Health Care and Quality. 2012-2017. GH Direct Costs: \$ 229,184. % Effort: 10%.
 49. Co-Investigator. Studying Colorectal Cancer Effectiveness of Screening Strategies (SuCCES)-Cervical Unit Supplement. U54CA163261 National Cancer Institute. (Principal Investigators: Carolyn Rutter and Aruna Kamineni). 2014-2016. GH Direct Costs: \$ 811,431. % Effort: 8%.
 50. Co-Investigator (Site Principal Investigator). Comparative Modeling: Informing Breast Cancer Control Practice & Policy. U01 CA152958. Funded by National Cancer Institute. (Principal Investigator: Jeanne Mandelblatt.) 2012-2016. GH Direct Costs: \$71,112. % Effort: 2%.
 51. Co-Investigator. Systematic Evidence Reviews to Support the U.S. Preventive Services Task Force (USPSTF) - Thyroid Cancer. HSA290201200015i. Agency for Healthcare Research and Quality. (Principal Investigator: Evelyn Whitlock) 2014-2016. GH Direct Costs: \$ 233,517. % Effort: 8%.
 52. Co-Investigator (Site Principal Investigator). Evaluating G-CSF Use in Cancer Patients. U24 CA171524. Funded by National Cancer Institute. (Principal Investigator: Pam Pawloski.) 2014-2015. GH Direct Costs: \$ 12,150. % Effort: 0%.

53. Co-Investigator (Site Principal Investigator). Breast Cancer Surveillance Consortium Data Resource. Contract HHSN26120110003. Funded by National Cancer Institute. (Principal Investigator: Ellen O'Meara.) 2011-2016. GH Direct Costs: \$2,344,000. % Effort: 10%.
54. Co-Investigator. Supporting Provider Engagement in Improving Value in Health Care. 72546. Robert Wood Johnson Foundation. (Principal Investigator: Michael Parchman.) 2015-2016. GH Direct Costs: \$601,951. % Effort: 10%.
55. Co-Investigator (Site Principal Investigator). Exploring Opting Out of Lung Cancer Screening Participation in Long-Term Smokers. U24 CA171524. National Cancer Institute. (Principal Investigator: Larry Kushi.) 2015-2016. GH Direct Costs: \$24,920. % Effort: 1%.
56. Co-Investigator. Comparative Effectiveness of Surveillance imaging Modalities in Breast Cancer Survivors. CE-1304-6656. Patient Centered Outcomes Research Institute. (Principal Investigator: Karen Wernli.) 2013-2016. GH Direct Costs: \$1,542,773. % Effort: 10%.
57. Co-Investigator. Comparative Modeling: Informing Breast Cancer Control Practice and Policy. National Cancer Institute. (Principal Investigator: Jeanne Mandelblatt) 2015-2020. GH Direct Costs in year 1: \$20,322. % Effort: 2%.
58. *Co-Investigator (Site Principal Investigator). Comparative Effectiveness of Preoperative Breast MRI on Surgery and Outcomes. R01 CA149365. Funded by National Cancer Institute. (Principal Investigator: Tracy Onega.) 2011-2017. GH Direct Costs: \$695,000. % Effort: 5%.
59. Project Co-Lead. Risk-Based Breast Cancer Screening in Community Settings. P01 CA154292. Funded by National Cancer Institute. (Principal Investigators Karla Kerlikowske and Diana Miglioretti.) 2011-2017. GH Direct Costs: \$ 23,965,000. %Effort: 25%.
60. Co-Investigator (Site Principal Investigator). Mammography Challenge Project. Laura and John Arnold Foundation. (Principal Investigator: Stephen Friend.) 2015-2017. GH Direct Costs: \$51,050. % Effort: 5%.
61. Co-Investigator. Implementing the Action Framework of RWJF's Supporting Provider Engagement in Value in Health Care Program, Phase 2. Robert Wood Johnson Foundation. (Principal Investigator: Michael Parchman) 2016-2018. GH Direct Costs in Year 1: \$1,007,652. % Effort: 7%
62. Steering Committee member for AcademyHealth, PCORI funded, "Defining Patient-Centered Metrics for Low-Value Care". 2016-2018. %Effort: 0%.
63. Principal Investigator. Risk of New Malignancies Following Breast Cancer. HHSN261201700564P. National Cancer Institute. 2017-2018. Direct costs: \$92,873. % FTE: 10%.
64. Co-Lead of the CRN Scholars Program and Co-Investigator. CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems. U24 CA171524. Funded by National Cancer Institute. (Principal Investigator: Larry Kushi.) 2012-2019. KPWA Direct Costs: \$ 1,899,000. % Effort: 15%.
65. *Co-Investigator (Site Principal Investigator). Site Principal Investigator. Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women. R01 CA168598. National Cancer Institute. (Principal Investigator: Rachel Winer.) 2012-2019. KPWA Direct Costs: \$ 1,626,000. % Effort: 20%.

66. Site PI, Co-Investigator. Comorbidity and Screening Outcomes among Older Women Undergoing Mammography. R01 CA207361. National Cancer Institute. (Principal Investigator: Dejana Braithwaite) 2016-2020. KPWA Direct costs in year 1: \$122,139. % Effort: 10%.

CURRENT RESEARCH GRANTS (as Principal Investigator or Co-Investigator)

1. Co-Investigator. Comparative Effectiveness of Breast Cancer Screening and Diagnostic Evaluation by Extent of Breast Density. Patient Centered Outcomes Research Institute. PCS-1504-30370. (Principal Investigators: Diana Miglioretti, Karla Kerlikowske, Tracy Onega, Anna Tostetson.) 2016-2021. KPWA Direct Costs in year 1: \$751,374. % FTE: 10%.
2. Site PI, Co-Investigator (site Principal Investigator). The Effectiveness, Safety, and Costs of Guideline-Concordant Lung Nodule Care. R01 CA207375. National Cancer Institute. (Principal Investigator: Farhood Farjah) 2017-2020. KPWA Direct Costs: \$347,489. % FTE: 10%.
3. Site PI, Co-Investigator. Risk-based Breast Cancer Screening and Surveillance in Community Practice. P01 CA154292. National Cancer Institute. (Principal Investigators: Diana Miglioretti, Karla Kerlikowske, Anna Tostetson.) 2017-2022. KPWA Direct Costs: \$279,000. % FTE: 15%.
4. Principal Investigator. Risk of New Malignancies Following Breast Cancer - Tissue sub-study. National Cancer Institute. 2018-2019. KPWA Direct Costs in year 1: \$15,479. % FTE: 7%.
5. Site Principal Investigator, Co-Investigator. Using a Mixed Methods Approach to Understand Shared Decision-Making in Lung Cancer Screening. R01 CA222090. National Cancer Institute. (Principal Investigator: Lisa Carter Harris). 2018-2022. KPWA Direct Costs: \$855,000. % FTE: 25%.
6. Co-Investigator. Multilevel Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations. UM1 CA221940. National Cancer Institute. (Principal Investigator: Jasmin Tiro.) 2017-2022. KPWA Direct Costs: \$3,472,000. % FTE 5%.
7. Principal Investigator. CATALyST: Consortium for Applied Training to Advance the Learning Health System with Scholars/Trainees. K12 HS026369. Agency for Healthcare Research and Quality. 2018-2023. KPWA Direct Costs: \$3,400,000. % FTE 10%.
8. Co-Principal Investigator (contact). Self-Testing options in the Era of Primary HPV screening for cervical cancer (STEP) trial. R01 CA240375 (Buist/Winer). National Cancer Institute. 2019-2024. KPWA Direct Costs: 2,858,550. % FTE: 25%.
9. Principal Investigator. Risk of New Malignancies Following Breast Cancer – Radiotherapy. National Cancer Institute. 2018-2019. KPWA Direct Costs: \$92,773 % FTE: 5%.
10. Principal Investigator. Risk of New Malignancies Following Breast Cancer – Mammographic breast density. National Cancer Institute. 2018-2019. KPWA Direct Costs: \$92,734 % FTE: 5%.

PENDING RESEARCH GRANTS (as Principal Investigator or Co-Investigator)

1. Co-Investigator. SMS/REACH Investigation to the Microbiome. National Cancer Institute. (Principal Investigator: Polly Newcomb). 2019-2021. KPWA Direct Costs in year 1: \$35,647. % FTE: 4%.
2. Co-Investigator/project lead. Optimizing Implementation in Cancer Control. (Multiple Principal Investigator: Bryan Weiner, Patricia Hannon, Cara Lewis). Project title: Patient-Centered Approach to Tailoring HPV Self-Sampling for Cervical Cancer Screening (PATH). P50. 2019-2023. KPW Total Direct Costs: \$2,075,077. % FTE: 10%.

RESEARCH GRANTS (as Consultant)

1. Prospective Study of Breast Cancer Survivorship. R01 Funded by the National Cancer Institute (Principal Investigator, Larry Kushi). 2004-2009.
2. Comparative Modeling: Informing Breast Cancer Control Practice & Policy. U01 CA152958. Funded by National Cancer Institute. (Principal Investigator: Jeanne Mandelblatt). 2010-2012.

CONFERENCES AND SYMPOSIUMS

1. **Buist DSM**, Chang JC, Garcia M, Melkote R, Brass LM. Trends and implications of cerebrovascular disease in the Veterans Administration. American Public Health Association, November, 1994.
2. **Buist DSM**, Schoendorf K, Kiely J. The association between breastfeeding and reported respiratory disease among infants exposed to maternal tobacco smoke. American Public Health Association, San Diego, California, October, 1995.
3. Newton KM, LaCroix AZ, **Buist DSM**. The use of alternative and complementary medicine by women enrolled in an HMO setting. HMO Research Network Conference. Oakland, California, May, 1998.
4. **Buist DSM**, LaCroix AZ, Barlow WE, White E, Weiss NS. Does bone mineral density predict breast cancer risk in postmenopausal women? American Society of Preventive Oncology. Houston, Texas, March 1999.
5. Donahue J, Andrade S, Beck A, Boles M, **Buist D**, Chandler J, Chase G, Ettinger B, Goodman M, Guess H, Gurwitz J, LaCroix A, Levin TR, Platt R. Multi-HMO assessment of alendronate and gastro-duodenal perforation, ulcer or bleeding. Pharmaceutical Outcomes Research: Past, Present and Future. Seattle, Washington, April 1999.
6. LaCroix AZ, Anderson LA, Newton KM, **Buist DSM**, Delaney KM. Qualities of HRT Counseling: Findings from the EnPower Study. National Menopause Society. New York, New York, September, 1999.
7. Newton KM, LaCroix AZ, **Buist DSM**, Anderson LA, Delaney KM. Will women in managed care use a mailed HRT workbook? The EnPower Study Workbook Trial. National Menopause Society. New York, New York, September, 1999.
8. **Buist DSM**, LaCroix AZ, Manfredonia D, Abbott T. Prevalence of osteoporosis among postmenopausal women in a managed care setting. American Society for Bone and Mineral Research Society. St. Louis, Missouri, September, 1999.

9. Chang S, **Buist D**, Reid M, Terry MB, Trentham-Dietz A. ASPO 2001 survey findings. American Society for Preventive Oncology. Bethesda, Maryland, March 2002.
10. *Young LE, Cunningham SL, **Buist DSM**. Heart health determinants in lone versus partnered mothers: National Health and Nutrition Examination Survey III (NHANESIII). AHA, Honolulu, HI April 2002.
11. *Casso D, **Buist DSM**, Taplin. Quality of Life of 5-10 Year Breast Cancer Survivors Diagnosed Between Ages 40 and 49. HMO Research Network Conference, Long Beach, CA, April 2002.
12. Andrade SE, Majumadar SR, Chang KA, **Buist DS**, Go AS, Goodman M, Smith DH, Platt R, Gurwitz JH. Treatment of Osteoporosis Among Older Women Following an Osteoporotic Fracture. International Society for Pharmacoepidemiology. Edinburgh, Scotland. August 2002.
13. Brenneman SK, LaCroix AZ, **Buist DSM**, Chen Y, Abbott TA. Evaluation of the sensitivity and specificity of screening tools for referring women for bone densitometry. American Society of Bone and Mineral Research. San Antonio, TX, September 2002.
14. LaCroix AZ, **Buist DSM**, Abbott TA, Brenneman SK. The Osteoporosis Population-Based Risk Assessment trial (OPRA) comparing three screening strategies for fracture prevention. American Society of Bone and Mineral Research. San Antonio, TX, September 2002.
15. *Park A, **Buist DSM**, Taplin SH. Mammography participation among low-income women in a staff model HMO. AACR Frontiers in Cancer Prevention annual meeting, Boston, MA, October 2002.
16. **Buist DSM** (Invited). Multi-site data aggregation: An example from a CRN-CERT collaboration to examine HRT diffusion from 1999-2002. HMO Research Network Meeting. Dearborn, Michigan. 2004.
17. *Crest AB, Aiello EJ, Anderson ML, **Buist DSM**. Varying levels of family history of breast cancer in relation to mammographic breast density. American Society of Preventive Oncology. San Francisco, CA. 2005.
18. **Buist DSM**, Aiello EJ, Miglioretti D, Mahoney L, White E. Mammographic breast density, dense area and breast area by phase in the menstrual cycle. San Antonio Breast Symposium. San Antonio, TX. December 10, 2005.

EDUCATIONAL MATERIALS

- To be or not to be on hormone replacement therapy.
- Bone health for a lifetime. A guide to the prevention and management of osteoporosis.

TEACHING HISTORY

- 1997-present Faculty, American Thoracic Society's International Course: Methods in Epidemiologic, Clinical and Operations Research, 6 day course, 60 hours of didactic instruction each year.
- 1998 Lecturer, Epidemiologic study design, Human Biology Epidemiology, University of Washington's School of Medicine, one quarter class, once/week.

- 1998-1999 Huckabay Teaching Fellow, University of Washington, Seattle, Washington, one quarter class, 3 units.
- 1998-2000 Faculty, Expand Your Horizon's. Seattle, Washington, 8 hours each year.
- 1999, 2003 Case-cohort studies. Advanced Epidemiologic Methods Course, University of Washington's School of Public Health and Community Medicine, guest lecturer for 1 ½ hours each year.
- 2000, 2006 Organizer, Faculty, Epidemiology 101, Group Health* Center for Health Studies, Seattle, Washington, 10 week course, 1 ½ hours/week.
- 2004 Faculty, Veterans Administration's Epidemiology, Biostatistics and Clinical Research Methods Summer Session. University of Washington, 8 hours of instruction.
- 2010 Faculty, Methods and Applications for Comparative Effectiveness Research, Institute of Translational Health Services, University of Washington, September 2010
- 2012 Faculty, Biennial Outcomes Course, American College of Surgeons, Chicago IL, November 2012.
- 2015 Quality versus Quantity: A rational approach to healthcare in the era of healthcare reform. Continuing Medical Education. Group Health Cooperative. Hawaii.

ADVISING AND FORMAL MENTORING

PHD DISSERTATIONS

1. Doctoral dissertation committee member, Jessica Chubak, PhD student in Epidemiology, University of Washington, School of Public Health and Community Medicine, 2003-2007.
2. Doctoral dissertation committee member, Amanda Phipps, MPH, PhD student in Epidemiology, University of Washington, School of Public Health and Community Medicine, 2008-2010.
3. Doctoral dissertation committee member and Research Associate Supervisor, Elisabeth Beaber, MPH, PhD student in Epidemiology, University of Washington, School of Public Health and Community Medicine, 2008-2012.
4. Doctoral dissertation committee member, Heidi Wirtz, PhD student in Pharmaceutical Outcomes Research, University of Washington, School of Pharmacy, 2010-2014.
5. Doctoral dissertation committee member, Maria Agapova, PhD student in Pharmaceutical Outcomes Research, University of Washington, School of Pharmacy, 2013-2016.
6. Doctoral dissertation committee member, Colin Malone, MPH; PhD student in Epidemiology, University of Washington, School of Public Health, 2013-present.

MASTERS THESES

1. Supervisor and Thesis committee member, Anthony Crest, MPH student in Public Health Genetics, University of Washington, School of Public Health and Community Medicine. Graduated June 2005.
2. Supervisor and Thesis Chair, Megan Welsh MPH student in Epidemiology, University of Washington, School of Public Health and Community Medicine, 2005-2006.

MENTORED SCIENTISTS AND POSTDOCS

1. Community Project Faculty Advisor to Christian Loch, PhD, MPH student in Epidemiology, University of Washington, School of Public Health and Community Medicine. 2005-2006. Currently Director of Research and Development at AVMBioMed.
2. AHRQ K12 Comparative Effectiveness Research Scholar Mentor to Karen Wernli, PhD, MPH. 2010-2013. Currently an Assistant Investigator at Group Health Research Institute.*
3. Eva Chang, PhD, Group Health Foundation Post-Doctoral Fellow. 2014-2015. Currently a Research Scientist at Research Triangle Institute.

ACADEMIC ADVISING

1. TL1 Mentor for Melissa Romaine, MS trainee. PhD student in Health Services, University of Washington, School of Public Health, 2009-2011.
2. Research Associate Supervisor, Sarah Lowry, MPH, PhD student in Epidemiology. University of Washington School of Public Health. 2010-present.
3. Research Associate Supervisor, Amanda Phipps, MPH; PhD student in Epidemiology, University of Washington, School of Public Health, 2006-2007.
4. Nora Schentschischin (now Knight Ross), MS student in Health Care Innovation Student. Maastricht University. Faculty mentor for internship. Topic, "The uptake of the health profile, a tool for risk assessment." Summer 2009.
5. Research Associate Supervisor, Hannah Cohen-Cline, MPH student in Epidemiology, University of Washington, School of Public Health, 2010-2012.
6. Research Associate Supervisor, Elisabeth Beaber, PhD student in Epidemiology, University of Washington, School of Public Health, 2009-2012.
7. Research Associate, Colin Malone, MPH; PhD student in Epidemiology, University of Washington, School of Public Health, 2013-present.